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patients were left  in a poor clinical condition 
at hospital discharge. Th e surgically treated 
patients were younger, had larger ICHs and 
their level of consciousness on arrival was 
lower than the conservatively treated patients. 
Although surgically treated patients were left  
in a poor condition, no data exist on long-
term functional outcome and recovery aft er 
intracerebellar haemorrhage. More studies are 
needed.
ICH-related hydrocephalus is usually con-
sidered a predictor of poor outcome. In our 
series, hydrocephalic patients had very high 
mortality, but surgical treatment – either by 
external ventricular drainage or evacuation of 
a hydrocephalus-causing cerebellar ICH – was 
associated with lower in-hospital and 3-month 
mortality. Only a small subgroup of all hydro-
cephalic patients received surgical treatment, 
but a diff erence in mortality between surgi-
cally and conservatively treated patients was 
observed in a propensity-matched case-con-
trol comparison. Th e high mortality previ-
ously attributed to ICH-related hydrocephalus 
may be a self-fulfi lling prophecy.
ICH in the young was caused most oft en by 
hypertension and structural vascular anom-
alies such as arteriovenous malformations or 
cavernous angiomas. Th e predictors of poor 
outcome did not diff er from those in older 
patients, these being Glasgow coma score < 8, 
infratentorial location, intraventricular blood, 
hydrocephalus, and haematoma volume > 30 
ml. However, surgical treatment was associ-
ated with signifi cantly lower mortality than 
conservative treatment.
In conclusion, surgical treatment was 
associated with a lower short- and long-term 
mortality in patients with ICH-related hydro-
cephalus and in young adults. More studies are 
needed to elucidate the advantages and disad-
vantages of surgical treatment in patients with 
intracerebellar haemorrhage and ICH-related 
hydrocephalus. 
ABSTRACT
Intracerebral haemorrhage (ICH) is a deadly 
subtype of stroke with an average 12-month 
mortality exceeding 50%. Th e most common 
causes for ICH include hypertensive microan-
giopathy, amyloid angiopathy, antithrombotic 
or anticoagulant medication, or systemic dis-
eases. Despite advances at other frontiers of 
stroke treatment, treatment options for ICH 
are limited. Neurosurgical treatment for ICH 
has been discussed in recent multicentre stud-
ies, but no defi nitive answer of its utility has 
emerged. Age, ICH volume and location, and 
extent of ventricular haemorrhage among 
other factors aff ect the prognosis aft er ICH. 
We studied the diff erent prognostic scores for 
ICH to fi nd the best tool for estimation of the 
risk of death aft er ICH. One of the best known 
is the ICH score, published in 2001. In addi-
tion, we studied the eff ect of neurosurgical 
treatment (1) in patients with intracerebellar 
haemorrhage; (2) in patients with ICH-re-
lated hydrocephalus; and (3) in young adults 
in an observational, retrospective analysis of 
consecutive ICH patients admitted to Hel-
sinki University Hospital during a fi ve-year 
period. Traumatic and aneurysmal ICHs were 
excluded from the study.
We found 19 prognostic scores, many of 
which were based on the original ICH score. 
For estimating the risk of in-hospital death, 
the National Institutes of Health Stroke Scale 
performed as well as the best dedicated scores. 
For 3- and 12-month mortality, the ICH Func-
tional Outcome Scale (ICH-FOS) performed 
best. However, all prognostic scores share the 
risk of self-fulfi lling prophecies, the estimated 
poor outcome resulting in limitations of care.
Based on a mutual consensus among neurol-
ogists and neurosurgeons, cerebellar ICH is 
usually treated surgically in patients with a 
declining level of consciousness and a large 
haematoma. However, in our series, surgical 
and medical treatment did not diff er in short- 




Aivojensisäisen verenvuodon kirurginen hoito ja ennuste
Tutkimuksen taustaa
Aivojensisäinen verenvuoto on äkillinen ja 
tappava sairaus, johon sairastuneista yli puolet 
menehtyy vuoden sisällä. Vuodon tavallisim-
pia syitä ovat hitaasti kehittyvät rappeuma-
muutokset aivojen pienissä valtimoissa esi-
merkiksi verenpainetaudin seurauksena ja 
veren hyytymiseen vaikuttavat lääkkeet. Aivo-
jen sisällä verihyytymä vaurioittaa aivokudosta 
paikallisesti repien harmaan ja valkean aineen 
hermoratoja, kun taas veren aiheuttama kemi-
allinen ärsytys ja painevaikutus aiheuttavat 
lisävaurioita sitä ympäröiviin rakenteisiin. 
Aivojensisäisen verenvuodon ennuste riip-
puu vuodon sijainnin ja koon lisäksi potilaan 
iästä, taustasairauksista ja aiemmasta lääki-
tyksestä. Ennusteen arviointiin on kehitetty 
lukuisia pisteytysmalleja. Leikkaushoidon 
vaikutusta kuolleisuuteen on aiemmin selvi-
tetty laajoissa satunnaistetuissa monikeskus-
tutkimuksissa, eikä kiistatonta näyttöä sen 
hyödyistä ole saatu. Leikkaushoitoa kuitenkin 
harkitaan nuorilla potilailla sekä silloin, kun 
hyytymä sijaitsee pikkuaivoissa ja painaa aivo-
runkoa tai tukkii aivo-selkäydinnestekierron. 
Tutkimuksen toteutus
Tässä väitöskirjassa tutkittiin aivojensisäisen 
verenvuodon hoitotuloksia Helsingin yliopis-
tollisessa keskussairaalassa vuosina 2005-2010 
yli tuhannen potilaan aineistossa, keskittyen 
kirurgisesti hoidettuihin potilasryhmiin: pik-
kuaivovuodon saaneisiin potilaisiin, nuo-
riin aikuispotilaisiin ja niihin, joille kehittyi 
vuodon seurauksena aivo-selkäydinnestekier-
ron häiriö eli hydrokefalus. Lisäksi tutkimme, 
mikä olemassa olevista 19 pisteytysmallista 
ennustaa parhaiten vuodonjälkeistä kuollei-
suutta. Kyseessä oli takautuva asiakirjatutki-
mus.
Tutkimuksen tulokset
Totesimme, että pikkuaivovuodon kirurgisen 
hoidon tulokset olivat odotettua heikommat 
– leikattujen ja lääkkeellistä tuki- ja tehohoi-
toa saaneiden potilaiden kuolleisuus oli yhtä 
suurta. Leikkauksen ansiosta osa todennäköi-
sesti jäi henkiin, mutta huonokuntoisiksi jää-
neiden vuodepotilaiden osuus oli leikattujen 
potilaiden ryhmässä merkittävästi suurempi. 
Tuloksemme vahvistavat viimeaikaisia havain-
toja, joiden mukaan pikkuaivovuodon leik-
kaushoito ei ole niin hyödyllistä kuin yleensä 
ajatellaan.
Kuolleisuus oli erittäin runsasta myös niillä 
potilailla, joille kehittyi vuodon seurauksena 
aivo-selkäydinnestekierron häiriö. Aiempien 
tutkimusten perusteella arvelimme, että leik-
kaushoito ei merkittävästi parantaisi ennus-
tetta. Leikattujen potilaiden kuolleisuus oli 
kuitenkin yllättäen merkittävästi pienempää 
kuin lääkkeellistä teho- ja tukihoitoa saaneilla 
potilailla. 
Myös nuorten aikuispotilaiden leikkaus-
hoito vuodon sijainnista riippumatta paransi 
ennustetta lääkkeellistä tuki- ja tehohoitoa 
saaneisiin potilaisiin verrattuna. Pisteytysmal-
leista totesimme, että aivoverenkiertohäiriön 
vaikeusasteen arviointiin tarkoitettu Natio-
nal Institutes of Health Stroke Scale (NIHSS) 
ennusti parhaiten sairaalassa tapahtuvaa 
kuolleisuutta, kun taas kolmen kuukauden 
ja vuoden kuluttua vuodosta kuolleisuutta 
ennusti parhaiten tähän tarkoitukseen kehi-
tetty ICH Functional Outcome Score (ICH-
FOS).
Loppupäätelmät
Aivojensisäisen verenvuodon leikkaushoidon 
tulokset Helsingin yliopistollisessa keskussai-
raalassa olivat odotettua paremmat nuorilla 
Tiivistelmä
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aikuisilla vuodon sijainnista riippumatta sekä 
niillä potilailla, joilla vuoto aiheutti aivo-sel-
käydinnestekierron häiriön. Pikkuaivovuodon 
saaneilla potilailla taas leikkauksen hyödyt 
jäivät odotettua pienemmiksi. Hoitovaihto-
ehtoja tulee arvioida kaikilla aivojensisäisen 
verenvuodon saaneilla potilailla yksilölli-
sesti ja harkita leikkaushoitoa niillä potilailla, 





AD  Alzheimer disease
AHA  American Heart Association
APOE  Apolipoprotein E
ASA  American Stroke Association
AUC  Area under curve
AVF  Arteriovenous fi stula
AVM  Arteriovenous malformation
BP  Blood pressure
CAA  Cerebral amyloid angiopathy
CI  Confi dence interval
CSF  Cerebrospinal fl uid
CSVD  Cerebral small vessel disease
CT  Computerised tomography
CTA  Computerised tomography angiography
dAVF  Dural arteriovenous fi stula
DC   Decompressive craniectomy 
ESO  European Stroke Organisation
EVD  External ventricular drainage
GCS  Glasgow Coma Scale
Hb  Haemoglobin
HR  Hazard ratio
HUH  Helsinki University Hospital
ICD-10  International Classifi cation of Diseases, 10th version
ICH  Intracerebral haemorrhage
IQR  Interquartile range
IS  Ischaemic stroke
IVH  Intraventricular haemorrhage
MRI  Magnetic resonance imaging
mRS  Modifi ed Rankin Scale
NIHSS  National Institutes of Health Stroke Scale
NPV  Negative predictive value
OR  Odds ratio
PPV  Positive predictive value
ROC  Receiver operating curve
RR  Relative risk
rTPA  Recombinant tissue plasminogen activator
SAH  Subarachnoid haemorrhage
SD  Standard deviation
Abbreviations
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1  INTRODUCTION
Intracerebral haemorrhage (ICH) is a deadly 
subtype of stroke with an average 12-month 
mortality exceeding 50%.1 Th e bleeding can be 
caused by a structural, macrovascular lesion 
such as cerebral artery aneurysm or arteri-
ovenous malformation (AVM). However, 
the majority of ICHs are microvascular, also 
called “primary” or “spontaneous”, originat-
ing from the small deep cerebral vessels.2 Th e 
most common causes for ICH include hyper-
tensive microangiopathy, amyloid angiopathy, 
antithrombotic or anticoagulant medication, 
or systemic diseases such as liver cirrhosis.3
Th e key to minimising stroke-related mor-
tality and morbidity is prevention – calcula-
tions from the Global Burden of Disease study 
show that 2/3 of all cerebral strokes could be 
prevented.4 Key targets for primary stroke pre-
vention are blood pressure lowering, smoking 
cessation, treatment with anticoagulant medi-
cation in patients with atrial fi brillation, daily 
aspirin and statin treatment in high-risk indi-
viduals, and screening for carotid artery ste-
nosis in patients suff ering a transient ischae-
mic attack (TIA).5
Sometimes prevention fails and a cere-
bral stroke occurs. Recent years have seen an 
increase in treatment possibilities for ischae-
mic stroke (IS), where thrombolysis and 
intra-arterial treatments have become rou-
tine, at least in specialist acute stroke centres.6 
However, in acute ICH, scientifi cally proven 
treatment options are limited. Th e current 
guidelines support rapid neuroimaging, med-
ical treatment of clinical seizures, blood pres-
sure lowering, treatment in specialist acute 
stroke unit, use of intermittent pneumatic 
stockings to prevent deep venous thrombosis, 
and multidisciplinary rehabilitation.7,8
Th e American Stroke Association (ASA) 
guidelines for the treatment of ICH also 
encourage the use of clinical prognostic scores 
as a routine part of evaluation.7 Th e most 
widely used prognostic score is the ICH score.9 
However, aft er its publication in 2001, prog-
nostic scores have become hugely popular, 
with nearly 20 scores since published. Th ese 
have rarely been compared with each other. 
Since the 1960s, surgical treatment of ICH 
has been considered controversial, especially 
in comatose patients.10 In 1989, a randomised 
controlled study was performed at the Helsinki 
University Hospital on surgical treatment of 
deep ICH. Th e study showed that the surviv-
ing patients were left  in very poor condition.11 
Newer, randomised studies have also failed to 
show substantial benefi t from surgical treat-
ment of ICH.11-14 However, a subgroup of ICH 
patients routinely undergoes surgical treat-
ment, namely patients with cerebellar ICH; 
there has been a wide mutual consensus in the 
neurological and neurosurgical communities 
that cerebellar ICHs should be operated. Nev-
ertheless, the scientifi c proof is mainly based 
on small retrospective series with confl icting 
results.15 To relieve brainstem compression 
and hydrocephalus, surgeons tend to favour 
surgical treatment in patients with a declining 
level of consciousness.16 Some regard this as 
counterintuitive, as the results on long-term 
outcome aft er surgery of cerebellar ICH are 
generally pessimistic.17
Intraventricular haemorrhage (IVH) and 
hydrocephalus also oft en require neurosurgi-
cal attention. ICH-related acute hydroceph-
alus and IVH have been found to be strong 
and independent predictors of poor functional 
outcome and mortality.18 Traditionally, acute 
hydrocephalus has been considered an indi-
cation for surgery in patients with a cerebellar 
ICH19, although strong evidence to support 
treatment of hydrocephalus in other types of 
ICH is virtually absent.20 IVH has been stud-
ied extensively, but there are no randomised 




We set out to study those subgroups of 
ICH patients that are most oft en encountered 
by the practicing neurosurgeon: patients with 
a cerebellar ICH or ICH-related hydroceph-
alus and young patients. Our objectives were 
to assess the diff erent outcome-modifying fac-
tors behind the prognostic scores for ICH, and 
the prognostic performance of the diff erent 
scores in a large, external cohort of consecu-
tive patients. We also studied the long-term 
and functional outcome aft er evacuation of 
cerebellar ICH, and the mortality aft er surgi-
cal treatment of ICH-related acute hydroceph-
alus. In addition, we investigated the eff ect of 
surgical treatment on mortality in young (16 
to 49 years) patients with ICH. 
Introduction
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2  REVIEW OF THE LITERATURE
2.1  Intracerebral haemorrhage (ICH)
2.1.1  Defi nition
Intracerebral haemorrhage (ICH) is defi ned 
as a focal collection of blood inside the brain 
parenchyma or the brain ventricles that is 
not caused by trauma.21 ICH can originate 
from structural or macrovascular structures, 
namely brain tumours, cerebral artery aneu-
rysms, arteriovenous malformations (AVM), 
dural arteriovenous fi stulae (dAVF), or cav-
ernous angiomas.22 Th e majority of ICHs are, 
however, caused by microangiopathic, i.e. 
degenerative changes in deep cerebral arteri-
oles.2 Intraparenchymal haemorrhages from 
arterial aneurysms were excluded from this 
literature review because of major diff erences 
in their pathogenesis, age distribution, and 
treatment.
2.1.2  Epidemiology
ICH constitutes around 9-27% of all types of 
stroke.23-25 Globally, the incidence of haemor-
rhagic stroke (ICH and aneurysmal SAH) has 
increased by 47% between 1990 and 2010.26 
While the number of patients with SAH has 
remained stable or even decreased in the last 
years, the ICH incidence has increased glob-
ally in low-income countries, probably due 
to the increasing prevalence of hypertension 
and smoking.23,27 Th e global mean overall 
incidence of ICH was 24.6 per 100 000 per-
son-years, varying markedly between diff erent 
racial and age groups. Th e incidence was simi-
lar in white, black, Hispanic, and Maori people 
but two times higher (incidence ratio 2.1) in 
South and Southeast Asian people.1
Age had a major infl uence in the inci-
dence, ranging from 1.9/100 000 person-years 
in patients under 45 years to 196/100 000 in 
patients over 85 years.1 In the Finnish popula-
tion, incidence has varied between 2/100 000 
in patients under 39 years and 222/100 000 in 
patients over 80 years.28 Th e mean age of Finn-
ish ICH patients was 69.5 years 29, and the total 
incidence has ranged from 17 to 35/100 000 
person-years.28,30,31
Globally, although age-standardised stroke 
mortality has decreased, the incidence and 
overall disease burden caused by stroke have 
increased – especially in low- and middle-in-
come countries.26 Noteworthy is that while the 
absolute number of ischaemic strokes (ISs) 
was twice that of haemorrhagic strokes the 
majority of the disease burden (deaths and 
disease-aff ected life-years, DALYs) was caused 
by haemorrhagic stroke, mainly in the low- 
and middle-income countries.32 Socio-eco-
nomic status also aff ected the ICH incidence 
in a Finnish population – Jakovljevic and 
colleagues33 noted that the age-standardised 
incidence of fi rst-ever ICH was approximately 
three times higher in men and four times 
higher in women in the low-income group 
than in the high-income group. 
In American urban teaching hospitals, 
the hospital admission rates for stroke have 
increased between 1990-1991 and 2000-2001. 
Th e increase in admissions was 19% for ICH 
patients, while the overall in-hospital mor-
tality decreased by 6%, from 29.9% to 28.1%. 
Ischaemic stroke admissions rose by 13%, 
while the in-hospital mortality decreased by 
36%, from 8.3% to 5.3%.34 Th e increase in 
admissions is probably caused by epidemio-
logical transition: greater number of elderly 
people and increases in the risk factors in the 
poor.35 While the acknowledgement and treat-
ment of risk factors for cardiovascular dis-
ease and recent advances in acute treatment 
options have reduced the mortality aft er IS in 
high-income countries, mortality aft er ICH 
remains quite high, both in high-income and 
in low-income countries.32,35 In a recent global 
meta-analysis, one-year survival aft er ICH was 
Review of the Literature
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as low as 46%, and 5-year survival strikingly 
low, 29%.36 In a single-centre follow-up study, 
mortality at 7 days, 1 year, and 10 years was 
31%, 59%, and 82%, respectively.37
2.1.3  Aetiology
2.1.3.1  Hypertensive microangiopathy
Th e most common cause of ICHs is hyper-
tensive microangiopathy, causing 35-60% of 
all ICHs.3,38 Hypertension, defi ned as > 140 
mmHg systolic or > 90 mmHg diastolic blood 
pressure 39, causes degenerative changes in the 
walls of perforating small arterioles, originat-
ing from the anterior, middle, or posterior 
cerebral arteries or the basilar artery. Con-
tinuously increased pressure in the arterioles 
damages the vessel walls and reduces vessel 
wall compliance.22 Th e original hypothesis 
by Charcot and Bouchard in 1868 was that 
hypertension would cause the formation of 
Figure 1. Examples of ICHs related to hypertensive microangiopathy or amyloid angiopathy in axial 
brain CT. (A) Hypertensive ICHs are oft en located in the deep brain structures, i.e. thalamus, basal 
ganglia, or internal capsule. (B) Intracerebral haemorrhages caused by amyloid angiopathy are, in con-
trast, oft en located cortically and may include multiple foci.
small miliary or microaneurysms in the walls 
of these small arterioles. Studies have since 
shown that the aff ected vessels have marked 
medial smooth muscle layer atrophy coexist-
ing with atherosclerosis, giving them the typ-
ical moth-eaten appearance, and the rupture 
site is usually in a vessel bifurcation in the 
distal lenticulostriate arteries.40,41
Hypertensive microangiopathy is a part of 
a larger vasculopathic phenomenon, cerebral 
small vessel disease (CSVD).42 In radiologic 
studies, CSVD presents as subcortical and 
periventricular white matter hyperintensities 
43, lacunar infarcts 44, and cerebral microbleeds 
.45 CSVD can cause a broad spectrum of symp-
toms. It has been associated with gait problems 
and incontinence 46, cognitive decline 47, and 
depression 48, and it may also contribute to the 
development of Alzheimer’s disease.49 Hyper-
tension-related ICHs are most oft en consid-
A
B
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ered to be located in the basal ganglia and tha-
lamic regions.50,51 History of hypertension was 
oft en present in patients with a lobar or a deep 
ICH, in 48-56% and 68-70%, respectively.3,38
2.1.3.2  Cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is the 
second most common cause for ICH, respon-
sible for about 20% of all ICHs and up to 80% 
of lobar ICHs.3,52 CAA causes deposition of 
beta-amyloid, formation of microaneurysms, 
and hyalinoid necrosis in the walls of small 
leptomeningeal and cortical arteries that can 
lead to vessel rupture and haemorrhage.53 
It has been recently shown that the degree 
of dilation in the juxtacortical perivascular 
spaces predicts the severity of CAA.54 Other 
biomarkers associated with CAA visible on 
magnetic resonance imaging (MRI) or tissue 
specimens are white matter hyperintensities, 
solely lobar cerebral microbleeds, and cortical 
superfi cial siderosis, i.e. deposition of haemo-
siderin in cortical sulci visible in MRI.55-57 Also 
apolipoprotein E (APOE) epsilon ( ) 2 and 4 
genotypes have been associated with the vas-
cular changes seen in CAA.58,59
Traditionally, CAA has been diagnosed 
from post-mortem or operative tissue speci-
mens with “Congo red” staining. It is a rather 
usual fi nding in the post mortem brain speci-
mens of the elderly with a frequency ranging 
up to 36% and 46% in over 60-year-old and 
over 70-year-old patients, respectively.60 How-
ever, tissue samples are somewhat impractical 
and hard to obtain – especially because a clini-
cal diagnosis of a probable CAA has tradition-
ally been considered a contraindication for 
surgical treatment due to diffi  culties in achiev-
ing postoperative haemostasis.61 However, in 
those patients that undergo surgical biopsy 
or post-mortem autopsy, CAA can be relia-
bly diagnosed in a small biopsy specimen.62 It 
has also been suggested that decreased levels 
of beta-amyloid in cerebrospinal fl uid (CSF) 
would serve as a preclinical biomarker for 
developing CAA.63
Th e Boston classifi cation was developed 
to aid the diagnosis of CAA on a clinical basis 
and it helps dividing patients into the catego-
ries of possible, probable, and defi nite CAA. 
Th e criteria state that even without a tissue 
specimen, CAA is probable in patients ≥ 55 
years, with imaging fi ndings of multiple cor-
tical, subcortical, or subcorticocortical haem-
orrhages in the absence of other causes of 
haemorrhage.52 However, autopsy studies have 
shown that in sporadic amyloid angiopathy, 
the incidence of ICHs was surprisingly low, in 
the range of 5.4-7.6%.64,65 Non-haemorrhagic 
and haemorrhagic CAA have been suggested 
to be linked to the diff erent APOE genotypes 
– APOE 2 genotype seemed to be associated 
with vasculopathy leading to haemorrhage, 
while APOE 4 was associated with the dep-
osition of amyloid in the vessel walls.55 In 
addition, CAA oft en coexists with Alzheimer 
disease (AD) – up to 95% of patients with AD 
had CAA fi ndings in autopsy samples. It has 
been demonstrated that the beta-amyloid pep-
tide found in vessel walls in CAA and senile 
plaques in AD is essentially similar.66
Together, hypertensive microangiopa-
thy and CAA account for around 55% of all 
ICHs.3 However, as most ICH patients do not 
undergo MRI to reveal the location of possible 
microbleeds and biopsy specimens are rarely 
available, the distinction between these two 
is somewhat unreliable. In patients diagnosed 
with “possible” CAA as per the Boston crite-
ria, 38% of patients were shown not to have 
CAA-related changes in autopsy specimens.52
2.1.3.3  ICH related to macro-vascular 
structural anomalies
Many macroscopic vascular and structural 
anomalies or diseases, such as brain arterio-
venous malformations (AVMs), dural arteri-
ovenous fi stulae (dAVF), and cavernous angi-
omas, also known as cavernomas, can cause 
intracerebral haemorrhage (Figure 2). Cere-
bral artery aneurysms can also cause an ICH, 
but because of the great diff erences in the 
Review of the Literature
16
presentation, outcome and treatment, these 
have intentionally been omitted from this lit-
erature review.
AVMs have been thought to be congeni-
tal and be formed in the embryonic phase,67 
during foetal development, or aft er birth.68 
Th ey consist of a feeding artery, a tangle of 
anomalous blood vessels that allow rapid blood 
fl ow between the artery and vein structures 
(nidus), and a draining vein.69 In the brain, 
the anomalous arteries lack a smooth muscle 
layer, while the anomalous veins have fi brous 
thickening of the vessel walls.70 Th e anoma-
lous vessels or aneurysms related to the high 
fl ow through the AVM may rupture and cause 
an ICH.71 While no single causative factor has 
been found, an epigenetic underlying mecha-
nism has been proposed.72 A recent study also 
suggested that single-nucleotide polymor-
phisms in the NOTCH4 gene could be associ-
ated with the development of AVMs.73
Th e estimated annual rupture risk in all 
AVMs is estimated to be 2.5-4.6%, being 
highest in large, deep-seated, infratentorial, 
or previously ruptured AVMs with associated 
aneurysms.71,74 Because of the rupture risk, 
AVMs can be treated by surgery, endovascu-
Figure 2. Diff erent types of structural causes for ICH. (A) A cerebellar AVM fi lling from superior, 
anterior inferior and posterior inferior cerebellar arteries in a digital subtraction angiography (DSA) 
image, vertebral artery injection, sagittal view. (B) A small, cortical, cavernous angioma in the pari-
etal lobe of the left  hemisphere in an axial T2-weighted MRI. (C) A large dAVF in the right occipital 
region. Th e fi stula is fed by the external carotid artery and it drains to the right transverse and sig-
moid sinuses. Coronal view of a DSA, right external carotid artery injection.
lar embolization, irradiation, or conservative 
management.75 In long-term follow-up, espe-
cially conservatively treated AVMs seem to 
carry a high risk of excess mortality relative 
to the non-aff ected population 76, although 
treatment of unruptured AVMs has also been 
associated with an increased risk of poor out-
come.77-79 However, compared with other ICH 
aetiologies, patients with an AVM-related 
haemorrhage seem to have a higher chance of 
good recovery.80
Dural arteriovenous fi stulae are another 
type of vascular malformation of the brain 
sometimes responsible for an ICH. Contrary 
to AVMs, dural arteriovenous fi stulae are 
thought to be mainly acquired lesions and 
occur usually in the vicinity of dural sinuses.81 
Th ey may be formed aft er cerebral venous 
sinus thrombosis, trauma, or intracranial 
surgery, but the underlying mechanism has 
not been established.82 Th e anomalous con-
nections form between the branches of dural 
or pial arteries and venous structures.83 Th ey 
have a risk of intracranial haemorrhage if the 
venous outfl ow is directed through the corti-
cal veins.84
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Brain cavernous angiomas are benign, 
vascular formations of dilated capillaries in 
the brain tissue that lack the normal vascular 
morphology, usually with a haemosiderin-rich 
layer in the surrounding brain tissue.85 Th ey 
are thought to form in the embryonic phase, 
but recent studies have shown growth by vas-
cular proliferation and neoangiogenesis of 
cavernous angiomas in adult patients.86 Aft er 
irradiation, de novo lesions with a similar 
histopathological appearance have also been 
observed.87
Cavernous angiomas can reside anywhere 
in the central nervous system88 and be spo-
radic or hereditary.89 Th ey oft en present with 
an epileptic seizure90, and the 5-year risk of 
subsequent epilepsy may be as high as 94%.91 
A cavernous angioma may bleed and cause 
a subclinical haemorrhage, acute massive 
haemorrhage, or slow oozing of red blood 
cells through the capillary walls.87 Th e risk of 
haemorrhage depends on the location and ini-
tial presentation, being highest in cavernous 
angiomas situated in deep, infratentorial or 
spinal locations.92,93 Th e 5-year risk of haem-
orrhage has been estimated between 2.4% and 
3.8% in patients without initial ICH and 29.5% 
to 30.8% in patients with a previously bleeding 
cavernous angioma.93,94
Surgical treatment has been suggested 
for cavernous angiomas that have previously 
ruptured to minimise the risk of re-rupture95 
and for those causing symptomatic epilepsy.90 
In surgery, it is considered important to 
remove not only the vascular malformation, 
but also the surrounding haemosiderin-rich 
rim because of its epileptogenicity.90,92,96 Th e 
outcomes aft er surgery are usually consid-
ered good.90 However, in a recent prospective 
observational study, surgical treatment of cav-
ernous angiomas was associated with a worse 
functional 5-year outcome than conservative 
management.97
2.1.4  General pathophysiology of 
ICH
Th e immediate injury aft er ICH is caused by 
local pressure, the so-called mass eff ect, and 
mechanical disruption of normal anatomy.98 
During the following hours and days second-
ary neuronal damage develops, caused mainly 
by the cytotoxicity of blood, excitotoxicity 
from glutamate that is released from the dam-
aged neurons, oxidative stress, infl ammation, 
and brain oedema.2,51,99,100 Red blood cells start 
to degenerate and release haemoglobin (Hb) 
into the brain tissue and CSF, which is then 
further degraded to iron and haem.98 Hae-
moglobin and its degradation products are 
highly cytotoxic and prone to cause oxidative 
damage.101 Multiple cellular systems take part 
in the transport, detoxifi cation and degrada-
tion these molecules, such as haptoglobin, a 
Hb-binding plasma protein produced in both 
the liver and oligodendrocytes102, CD163-pos-
itive macrophages that scavenge Hb103,104, and 
haem oxygenase-rich microglia that remove 
Hb and haem from the brain extracellular 
space.100
Intracerebral haemorrhage may also cause 
hydrocephalus. It is thought to arise partly 
from mechanical obstruction of the CSF fl ow, 
either by extraventricular compression or by 
intraventricular haemorrhage, and partly from 
the biological eff ects of the blood in the CSF.105 
Th e mechanical obstruction may happen at 
the level of interventricular foramina (foram-
ina of Monro), cerebral aqueduct, 4th ventricle 
outlets (foramina of Luschka and Magendie) 
in the posterior fossa, or arachnoid villi.106 
Formation of fi brosis has been observed at the 
level of both 4th ventricle outlets and arach-
noid villi.106,107
Haemoglobin degradation products, 
mainly iron, cause damage not only to the 
neurons but also to other types of brain cells. 
Iron and ferritin have been shown to accu-
mulate in the periventricular areas and hip-
pocampi in rats aft er intraventricular blood 
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injection and cause ependymal cell damage 
and death of ependymal cilia.108-111 IVH has 
been demonstrated to damage ependymal cell 
layer in the choroid plexus and cause disrup-
tion of the blood brain barrier.112 In addition, 
thrombin and activation of the coagulation 
cascade has been shown to be an individual 
causative factor in the formation of hydro-
cephalus aft er IVH.113
Hydrocephalus usually causes ventricu-
lar dilatation, which leads to ependymal cell 
damage in the choroid plexus and ventricular 
walls;105,112 periventricular gliosis; a decrease in 
the periventricular and, more generally, cere-
bral blood fl ow;114 an increase in the periven-
tricular extracellular space and water content 
in the cortical grey matter;115 and thinning of 
the white matter tracts and corpus callosum.116
Acute hydrocephalus related to ICH usu-
ally develops during the following hours or 
days aft er the ictus.18 It usually causes decline 
in the level of consciousness, headache, 
nausea, and may eventually lead to death if left  
untreated.117 If hydrocephalus develops more 
slowly, it can cause gait disturbance, urinary 
incontinence, and dementia, resembling idio-
pathic normal pressure hydrocephalus.118
2.2  Neurosurgical 
treatment of patients 
with ICH
Since the 1960s, surgical treatment of ICH 
has been considered controversial, especially 
in comatose patients.10 In 1989, a randomised 
controlled study was performed at our hos-
pital on surgical treatment of deep ICH. Th e 
study showed that the surviving patients were 
left  in a very poor condition.11 Th e subject has 
since been investigated extensively. 
In a large-scale, multicentre, randomised 
controlled trial (RCT), STICH13, Mendelow 
and co-workers randomised 1033 patients 
from 27 countries with a supratentorial ICH 
to initial conservative management (530 
patients) or early surgery (503 patients), in 
which the operation was carried out within 
24 hours of randomisation. Patients in the 
conservative group were able to cross over 
to the surgery group, and eventually, nearly 
one-quarter of the patients in the conservative 
treatment arm underwent surgery. Patients’ 
median age was 62 years, and median haemat-
oma volume was 38 ml. Only 24% of patients 
in the surgical group and 26% of patients in 
the medical treatment group had a favoura-
ble outcome, the diff erence being statistically 
insignifi cant. In addition, mortality did not 
diff er between the groups. In subgroup anal-
yses, those patients with a lobar haemorrhage 
located 1 cm or less from the surface showed 
some benefi t from surgery. 
Aft er conducting a meta-analysis of all 
available RCTs on surgical treatment of spon-
taneous supratentorial ICH119, the authors 
then designed another international multi-
centre RCT, STICH II14, to evaluate the afore-
mentioned subgroup from the original STICH 
trial. Th e STICH II trial recruited 601 con-
scious patients with a superfi cial, supratento-
rial, lobar ICH with a volume of 10 to 100 ml 
and without IVH. Th e patients were again ran-
domised to receive early surgery (less than 12 
hours from randomisation) or initial conserv-
ative management. Again, 21% of the patients 
in the conservative treatment group crossed 
over to the surgical treatment group. Th e 
results did not attain statistical signifi cance; 
62% of the patients in the initial conservative 
treatment group and 59% of the patients in the 
early surgery group had a poor functional out-
come at 6 months. 
It has been suggested that by using a tra-
ditional craniotomy approach, the surgeon-in-
duced trauma to the surrounding tissues could 
eventually negate the positive eff ects of hae-
matoma evacuation.120 In response, mini-in-
vasive techniques, such as endoscope-assisted 
aspiration and stereotactic aspiration have 
been studied.121
In a phase II randomised, international, 
multicentre trial, the MISTIE II trial, 96 
patients were randomised to receive either best 
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medical treatment (40 patients) or mini-in-
vasive catheter placement to the haematoma 
cavity, subsequent haematoma aspiration and 
clot irrigation with rTPA (56 patients).122 Th e 
outcome did not diff er between the groups, 
but the results proved that this was a viable 
approach. However, there was a higher rate 
of asymptomatic rebleeding in the surgical 
group. In further analyses of the MISTIE II 
data, mini-invasive surgery was associated 
with a decrease in perihaematomal oedema.123 
In the ongoing phase III MISTIE III trial, 
interim analyses revealed that the haematoma 
evacuation rate was up to 74%, and only 14% 
of the catheters required repositioning before 
administration of the rTPA.124 Th e fi nal results 
of the MISTIE III trial have not yet been pub-
lished. 
In addition to pharmacological clot 
removal, mini-invasive mechanical clot 
removal has also been used. Some studies 
have used endoscopic haematoma aspiration 
for evacuation of ICH or IVH. Already in 
1989, a RCT on endoscopic haematoma evac-
uation versus best medical treatment showed 
better survival in the surgical treatment group, 
although the functional outcome was similar 
between the groups.125 In 2016, MISTIE-ICES, 
a small subarm study of the MISTIE trial, con-
centrated on CT-guided endoscopic aspiration 
of supratentorial ICH.126 Patients with an ICH 
of over 20 ml were randomised 3:1 to receive 
either best medical treatment or endoscopic 
ICH aspiration. Th e study showed that the 
technique was safe, resulted in removal of over 
two-thirds of the haematoma, and patients 
treated with endoscopic haematoma evacua-
tion had a 12% greater likelihood of good out-
come at one year.
Numerous surgical tools have been devel-
oped to assist in mini-invasive removal of 
ICH. Using a navigated, rather large (diame-
ter 13.5 mm) tubular sheath (BrainPath endo-
port system, NICO, Indianapolis, IN, USA) to 
access the ICH cavity has been suggested.127 In 
addition, in the ongoing INVEST trial, image-
guided mini-invasive haematoma aspiration 
using a novel device combining irrigation, 
suction and vibration (Apollo System, Penum-
bra Inc, Alameda, CA, USA) is compared with 
best medical treatment.128 In another initial 
safety study, ICH was evacuated using a cath-
eter designed for intra-arterial thrombolysis 
inserted via a burr hole, combined with rTPA 
delivered into the haematoma cavity.129
Decompressive craniectomy for supraten-
torial ICH has also been suggested.130 In a 
small single-centre RCT, 40 patients divided 
into two groups were randomised to receive 
standard microsurgical haematoma evacu-
ation or a medium-size decompressive cra-
niectomy (DC) and duraplasty combined 
with the standard haematoma evacuation. DC 
was associated with better survival, especially 
in young patients.131 In a recent case-con-
trol study, 54 patients undergoing DC and 
haematoma evacuation were retrospectively 
compared with 72 patients who had received 
best medical treatment. Th e surgical treat-
ment was associated with increased survival, 
but no signifi cant diff erence emerged in func-
tional outcome between the groups.132 DC has 
been shown to be associated with increased 
perihaematomal oedema, although the mass 
eff ect was ameliorated by the surgical decom-
pression.133 A large multicentre RCT on DC 
versus best medical treatment in patients with 
a spontaneous deep ICH (SWITCH) is cur-
rently recruiting patients (https://clinicaltrials.
gov/show/NCT02258919).
As the large RCTs on surgical treatment of 
spontaneous supratentorial ICH have shown 
surgical treatment not to be superior to best 
medical treatment, the rate of ICH evacua-
tion has dropped and the rate of admissions 
to the Acute Stroke Units has risen, at least 
in the United Kingdom.134 We concentrated 
on three subgroups of ICH patients still fre-
quently referred to the neurosurgical service: 
patients with a cerebellar ICH, patients with 
ICH-related hydrocephalus, and young adults 
with ICH.
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2.2.1  Treatment of intracerebellar 
haemorrhage
Intracerebral haemorrhage (ICH) in the cer-
ebellum constitutes around 10% of all “spon-
taneous” non-traumatic, non-aneurysmal 
ICHs.135 Before computerized tomography 
became widely available, cerebellar ICH was a 
silent killer – patients deteriorated rapidly and 
the diagnosis was oft en made post mortem.136 
In 1978, Little and co-workers showed in a 
case series of 10 subjects that patients with cer-
ebellar ICHs over 3 cm in diameter benefi ted 
from surgical evacuation, while smaller ICHs 
could be treated medically.137 Since then, there 
has been a wide consensus in the neurological 
and neurosurgical communities that cerebel-
lar ICHs should be operated on, however, the 
scientifi c proof is mainly based on small retro-
spective series with confl icting results.15
Haemorrhage in the posterior fossa may 
cause brainstem compression and lead to 
impaired consciousness, respiratory failure, 
and lower cranial nerve dysfunction.136 Com-
pression or obstruction of the fourth ventricle 
may cause acute hydrocephalus.19 To relieve 
brainstem compression and hydrocephalus, 
surgeons tend to favour posterior fossa cra-
niectomy or craniotomy with haematoma 
evacuation in patients with a declining level of 
consciousness.16 Some regard this as counter-
Figure 3. Th ree locations of cerebellar ICH in axial brain CT. (A) A large, lateral hemispheric cere-
bellar ICH causing hydrocephalus and brainstem compression. (B) A vermian cerebellar ICH that 
compresses the fourth ventricle but does not obliterate it. (C) A small, medial hemispheric cerebellar 
ICH that does not have any mass eff ect.
intuitive, as the results for long-term outcome 
aft er surgery of cerebellar ICH are generally 
pessimistic.17
Th e recommendations for operative treat-
ment vary in the literature. Numerous diff er-
ent criteria have been suggested for surgical 
evacuation or decompression: haematoma 
diameter > 3 cm137, patients with brainstem 
compression138,139, patients with GCS 4-13 and 
haematoma diameter > 40 mm140, patients 
with a deteriorating level of consciousness 
and haematoma volume > 10 cm3141, and 
even all patients with a cerebellar ICH.142 In 
contrast, some authors do not recommend 
surgical treatment at all because of poor long-
term results.143 Clinicians usually tend to wait 
until clinical deterioration, and then proceed 
to operative treatment, especially in patients 
under the age of 70.16
Th e current treatment guidelines have con-
trasting recommendations regarding treat-
ment of cerebellar ICH. European Stroke 
Organisation (ESO) treatment guidelines did 
not fi nd strong evidence for when, how, or on 
whom surgical evacuation or decompression 
should be performed.8 American Heart Asso-
ciation (AHA) guidelines recommend evacu-
ation of cerebellar ICH in patients declining 
neurologically or suff ering from brainstem 
compression and/or acute hydrocephalus.7
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2.2.2  Treatment of ICH-related 
hydrocephalus
Acute hydrocephalus aft er ICH or IVH has 
been found to be a strong and independent 
predictor of poor functional outcome and 
mortality.18 Traditionally, acute hydroceph-
alus has been considered an indication for 
surgery in patients with a cerebellar ICH.19 
while strong evidence to support treatment of 
hydrocephalus in other types of ICH is virtu-
ally absent.20 Th e importance of hydrocephalus 
as an independent outcome-modifying factor 
aft er ICH was fi rst published as late as 1998.144 
Th e authors did not note any diff erences in 
mortality aft er EVD insertion, and the fi nding 
was later reproduced in a small case series.145 
Although some encouraging results have been 
published146, the majority of authors have 
found ICH-associated hydrocephalus to be a 
state of very high morbidity and it has been 
widely considered a sign of poor outcome.20,147
Regular treatment options for hydro-
cephalus are insertion of an EVD, sometimes 
combined with intraventricular fi brinolysis 
in patients with IVH, endoscopic third ven-
triculostomy, lumbar drainage, and insertion 
of a ventriculoperitoneal or ventriculoatrial 
shunt.148 Th ere have also been experimental 
reports on endoscopic third ventriculostomy 
for treatment of ICH-related hydrocephalus, 
especially combined with endoscope-assisted 
evacuation of IVH.149
Intraventricular fi brinolysis has been 
studied on hydrocephalic patients with IVH, 
where placing an EVD reduced mortality and 
increased rates of good functional outcome.150 
In a recently published large, double-blinded 
randomised trial of intraventricular alteplase 
versus saline, the patients who received 
alteplase had signifi cantly lower 180-day case 
fatality, but higher rates of poor functional 
outcome.151 In another study on intraventricu-
lar fi brinolysis, aggressive treatment with EVD 
and lumbar drainage signifi cantly reduced 
shunt-dependency compared with an EVD 
alone.152 However, no randomised studies on 
the treatment of ICH-related hydrocephalus 
have been published and there are no good 
criteria for when to place or remove an EVD.20
No randomised controlled trials exist on 
EVD placement for ICH-related hydrocepha-
lus, and the literature is overall quite scarce.20 
However, it has been suggested that EVD 
insertion in patients with IVH was associated 
with good outcome (modifi ed Rankin scale 
0-3) at discharge.150 In addition, multiple stud-
ies on the safety and effi  cacy of intraventricu-
lar fi brinolysis for treatment of IVH have been 
conducted in recent years. Using the recom-
binant tissue plasminogen activator (rTPA) 
alteplase, an intraventricular injection of one 
milligram every 8 hours via an EVD had the 
best effi  cacy and the lowest risk profi le.153,154 
It has also been shown that adding a lumbar 
drain aft er the third and fourth ventricles were 
cleared from blood was safe and signifi cantly 
reduced the rates of permanent shunt-depend-
ent hydrocephalus compared with patients 
with conventional EVD and intraventricular 
fi brinolysis.152,155
In a recent double-blinded randomised 
trial of intraventricular alteplase versus saline, 
the patients who received alteplase had signif-
icantly lower 6-month mortality, but higher 
rates of poor functional outcome.151 In the 
trial, all patients had an acute hydrocephalus 
and had received an EVD, aft er which the ran-
domisation was performed. Th e authors drew 
the conclusion that routine intraventricu-
lar fi brinolytic treatment cannot be recom-
mended in patients with IVH. It is, however, 
notable that the 6-month mortality in both 
groups was lower than that usually reported 
in studies of ICH-related hydrocephalus, 18% 
in the alteplase group and 29% in the saline 
group. Th e previously reported mortality rates 
of hydrocephalic ICH patients have varied 
between 55% (30-day mortality)147 and 71% 
(in-hospital mortality).145 One explanation 
for this diff erence may be that the patients 
were treated in a rather intensive fashion com-
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pared with the more conservative treatment 
accorded to the average ICH patient.
In previous studies, factors associated 
with shunt-dependent hydrocephalus have 
been thalamic ICH location, persistent high 
intracranial pressure (ICP), lower arrival GCS, 
and longer duration of external drainage. Th e 
shunting rate has varied between 20% and 
29%.156,157 In a recent review, the authors sus-
pected that 30-60% of patients needing an 
EVD would later need a shunt.154 Th e current 
guidelines are somewhat encouraging regard-
ing treatment of ICH-related hydrocephalus. 
Th e ESO guidelines do not give any strong 
recommendations about how, when, and 
for whom to place an EVD in the absence of 
RCTs. Th ey do state, however, that it seems 
reasonable to apply an EVD in cases of clinical 
or radiological signs of hydrocephalus based 
on small, non-randomized studies.8 Th e AHA 
guideline considers an EVD reasonable, espe-
cially in patients with a decreased level of con-
sciousness.7
2.2.3  ICH in the young
Young ICH patients are an important sub-
group. In young adults, aetiology of ICH is 
oft en diff erent than in the elderly.158 In addi-
tion, stroke aff ects not only the patients but 
their families as well, causing long-standing 
socio-economic consequences.159 However, 
young age has been identifi ed a positive prog-
nostic factor for better survival aft er ICH.9 As 
the incidence is higher in older age groups1, 
most of the research is concentrated on the 
general population and therefore older age 
groups. 
Contrary to the ICH incidence in the total 
population, it has decreased up to 47% in 
young adults in the United States between 1989 
and 2009, accounting for 34% of stroke-related 
deaths.160 Hypertension158,161, smoking58,161, 
hypocholesterolaemia, and excessive alcohol 
consumption are risk factors associated with 
ICH in the young.158
High numbers of patients with a structural 
aetiology have been observed,158,161,162 although 
in some studies hypertensive ICHs have also 
been prevalent.163,164 Short-term mortality has 
varied between 8% and 34%158,165, while long-
term mortality in the surviving patients was 
11.2% in a 10-year follow-up.166 A total all-
cause mortality of 31.4% aft er a 20-year fol-
low-up has been reported.167
2.3  Prognostic factors and 
ICH
Patients with ICH have very high mortality 
rates, overall mortality and morbidity being 
higher than in ischaemic stroke.168,169 In cur-
rent clinical practice, the prognosis is oft en 
based on the treating physician’s experience 
and assumptions.170 Overestimating the risk of 
death may lead to unnecessary withdrawal or 
limitation of treatment, while underestimat-
ing the risk of permanent unconsciousness 
or total dependence may lead to prolonged, 
futile treatment. Although the determination 
of “futile treatment” is complex, not least ethi-
cally, most clinicians consider that if the prob-
ability of survival was be around 5%, further 
treatment would be unethical and they would 
not recommend its continuation.171
Some attempts to predict the probability of 
death aft er an ICH had already been made in 
the last decades of 20th century172-174, but since 
the publication of the ICH score by Hemphill 
et al. in 20019, numerous diff erent scores have 
abounded in the neurological literature.  To 
our knowledge, none are in current, wide-
spread clinical use, with the possible exception 
of the original ICH score, although the most 
recent ASA treatment guidelines support the 
use of prognostic scores.7
Prognosis research has become more pop-
ular during the last 25 years, with nearly 100 
000 publications in 2015 (Figure 4). Th is is not 
surprising, as it is a central concept in clinical 
medicine, referring to the ‘risk of future health 
outcomes in people with a given disease or 
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condition’.175 Th e PROGnosis RESearch Strat-
egy (PROGRESS) partnership, a UK-based 
and Medical Research Council (MRC) 
-funded, international, interdisciplinary col-
laboration, was founded to improve the qual-
ity of research related to prognosis. Th ey have 
identifi ed four separate, but related research 
themes for prognosis research. 
1. Fundamental prognosis research175 should 
concentrate on defi ning the state and out-
come of current care, e.g. outcome aft er 
the rupture and subsequent treatment of 
a cerebral AVMs80, or the natural course 
(“natural history”) of the disease, e.g.  risk 
of rupture of untreated cerebral artery 
aneurysms.176 It is important for planning 
of future trials and health care policies (in 
defi ning the need for preventive measures), 
for understanding the absolute treatment 
eff ects of said diseases compared with the 
general population, and as a framework for 
researching clinical outcomes.
2. Research on prognostic factors177, which 
they defi ne as ‘any measure that, among 
people with a given startpoint (such as 
diagnosis of disease), is associated with a 
subsequent endpoint (such as death)’, con-
centrates on fi nding diff erent factors that 
divide patients into groups with a diff erent 
risk of, for example, death. Diff erent bio-
markers oft en serve as prognostic factors, 
such as the presence of untreated hyperten-
sion as a risk factor for ICH50, or the asso-
ciation of IVH with mortality aft er ICH.178 
Prognostic factors help in defi ning the 
severity of the disease and planning treat-
ment algorithms for diff erent subgroups, 
e.g. in low-grade glioma, where mutations 
in IDH1 gene and 1p19q co-deletions 
aff ect the outcomes and treatment deci-
sions are now based on these factors.179,180 
Once a prognostic factor has been identi-
fi ed, it should be tested in diff erent popula-
tions by, for instance, a meta-analysis.
3. Prognostic model research181 deals with 
risk calculators and scores. A prognostic 
model is defi ned as ‘- - a formal combi-
nation of multiple predictors from which 
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risks of a specifi c endpoint can be calcu-
lated for individual patients’. Research on 
prognostic models may concentrate on 
developing prognostic models, validat-
ing these in external cohorts, or assessing 
the clinical importance of said models. A 
good example is the ICH score9, a prognos-
tic score developed for assessing mortal-
ity aft er ICH. Th e authors state that good 
prognostic models should be developed 
with a large data, be based on a prospective 
study plan with pre-selected prognostic 
factors, and be validated in external patient 
cohorts.
4. Stratifi ed medicine research182, where the 
objective is on fi nding diff erent subgroups 
(strata) that benefi t from certain treatment. 
It is defi ned as ‘targeting of treatments - - 
according to the biological or risk charac-
teristics shared by subgroups of patients’. 
In cancer research and treatment this is 
becoming more and more ordinary, e.g. 
in diff erent subtypes of paediatric medul-
loblastoma, where treatment is tailored 
based on the results of genomic sequenc-
ing183. Such stratifi cation is oft en the end 
product of prospective, randomised stud-
ies concentrated on fi nding therapies for 
these subgroups.
However, prognosis research is oft en seen as 
riddled with problems, e.g. using small, retro-
spective cohorts without a pre-specifi ed sta-
tistical analysis plan181, selection of outcomes 
or prognostic factors that produce the “most 
signifi cant” p-values182, publication bias in 
favour of small studies with positive results184, 
and lack of external validation of prognostic 
models185. Th is has led to development of the 
TRIPOD (“Transparent Reporting of a mul-
tivariable prediction model for Individual 
Prognosis Or Diagnosis”) checklist, a report-
ing guideline for studies on prognostic models 
that concentrates on avoiding these issues186. 
Diff erent prognostic factors for mortal-
ity aft er ICH have been suggested. Th e ICH 
score9 includes the following variables (as do 
numerous later models): age, ICH volume, 
GCS, infratentorial location, and the presence 
of IVH Other suggested prognostic factors 
are National Institutes of Health Stroke Scale 
score (NIHSS) 168,187,188, comorbidities168,189-191, 
hyper- or hypotension187,190,192, out-of-hours 
arrival168, hyperglycaemia or diabetes190,191,193, 
dialysis190, cognitive decline194, fever187, low 
pulse pressure187, subarachnoid blood187, male 
gender168, atrial fi brillation168, coronary heart 
disease or peripheral artery disease168, absence 
of dyslipidaemia168, and the absence of previ-
ous stroke.168 Hydrocephalus has also been 
identifi ed as a strong prognostic factor for 
mortality aft er ICH, although it has not been 
included in prognostic scores.144
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3  AIMS OF THE STUDY
Th e series of studies concentrated on evaluation of prognostic scores for ICH and on neuro-
surgical treatment of ICH in the patient subgroups a neurosurgeon meets most oft en: young 
patients, hydrocephalic patients, and patients with a cerebellar ICH. Th e following questions 
were addressed:
1.  What is the best tool for mortality prognostication among the existing prognostic scores 
for ICH?
2.  How does medical or surgical treatment modify the outcome of patients with an intracer-
ebellar haemorrhage? 
3.  Does surgical treatment of patients with ICH-related hydrocephalus aff ect their mortal-
ity?
4. What is the outcome of young adults with ICH, and does surgical treatment aff ect their 
short- or long-term mortality? 
Aims of the Study
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4  PATIENTS AND METHODS
charts were retrieved. Patients with a trau-
matic haemorrhage, spontaneous epidural 
or subdural haemorrhage, or bleeding due to 
co-localised tumour (n=18) were excluded as 
non-strokes. Primary subarachnoid haemor-
rhage and haemorrhagic transformation of 
cerebral infarction (n=179) were excluded as 
well. 
4.1.2  Prognostic scores
A thorough search was performed in PubMed, 
OvidSP, Web of Science, and Google to include 
all available prognostic models for ICH pub-
lished aft er 1990. We used the search terms 
‘ICH’, ‘prognosis’, ‘score’, ‘scale’, and ‘validation’. 
None of the scores were used for clinical prog-
nostication at our institute.
We calculated all scores for each included 
patient. Th e FUNC score194 was derived to 
estimate good outcome instead of mortality, 
hence we used its reciprocal for the receiver 
operator curve (ROC) analyses. To deter-
mine the ICH volume, we preferred the same 
method as the original articles. Th e Graeb195 
and Hallevi196 IVH scores were determined. 
Th e Tuhrim equation174 included the IVH 
volume (cm3) estimated by computer-based 
image analysis. As this was not available at our 
centre, we used the mathematical method by 
Hallevi.196 Due to unavailability of some com-
puterized volumetric methods and structured 
questionnaires at our institute, we used the 
best possible alternatives.
4.1.3  Statistical methods
Th e accuracy of the scores was evaluated for 
three diff erent measures; 3-month all-cause 
mortality was chosen as the primary outcome, 
whereas in-hospital and 12-month mortality 
were measured as secondary outcomes. 
We analysed the univariate associations 
of all the diff erent score components and 
outcome. Th e ordinal and continuous score 
All of the studies (I-IV) were observational by 
nature and based on retrospective data col-
lected at the Departments of Neurology and 
Neurosurgery at Helsinki University Hospi-
tal. Th e hospital is a tertiary-level university 
teaching hospital, with a catchment popula-
tion of 1.8 million, which will increase to 2 
million in 2018 as the Päijät-Häme province 
joins the tertiary district. However, most of the 
ICH patients come from the Uusimaa prov-
ince with a population of 1.56 million, as the 
more distant secondary hospitals in Kotka 
and Lappeenranta have acute stroke units for 
conservative management of stroke patients. 
Helsinki University Hospital has the only neu-
rological and neurosurgical emergency rooms 
on a 24/7 basis, and it is a national refer-
ral centre for cerebrovascular neurosurgery. 
All data were collected retrospectively from 
charts, electronic patient records, and imag-
ing archives. Mortality data were derived from 
Statistics Finland’s National Death Registry. 
Th e Helsinki University Hospital adminis-
tration approved the study as a registry study 
with no patient contact or consent. Patients 
were treated according to ESO guidelines.8 All 
deaths were included regardless of the cause. 
A two-sided p < 0.05 was considered signifi -
cant for all analyses.
4.1  Publication I
4.1.1  Patients
For publication I, we used data from the 
Helsinki ICH study with 1013 consecutive 
patients admitted to the neurological emer-
gency department of our hospital between 
January 2005 and March 2010.3
Th e patients were identifi ed by the Inter-
national Classifi cation of Diseases, 10th version 
(ICD-10) code I61 during their stay in the 
acute phase or later during follow-up visits. 
Diagnosis data were retrieved from the elec-
tronic hospital discharge registry. All patient 
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components were tested for normality. Th e 
Kruskal-Wallis and Mann-Whitney U tests 
were used for skewed, and Analysis of Vari-
ance (ANOVA) for normally distributed data. 
Because of the time series nature of the anal-
ysis, we used Kaplan-Meier survival analysis 
with time from ICH to death up to 12 months 
as a continuous variable for the dichotomous 
score components. Th e Breslow-Wilcoxon test 
was used to evaluate univariate diff erences. 
To estimate the best possible prognos-
tic performance of all the score variables in a 
tailored logistic regression model, we divided 
the study population into derivation and val-
idation cohorts stratifi ed for age and ICH 
volume. Aft er stratifi cation by age and ICH 
volume, every other patient was classifi ed in 
the derivation and every other patient in the 
validation cohort. Th e cohorts were tested for 
statistically signifi cant diff erences. With all the 
score components forced to enter the model, 
a logistic regression model was constructed 
from the derivation cohort. We did not per-
form any dichotomization on either the con-
tinuous or the ordinal variables. Th e resulting 
model was tested on the validation cohort. 
We calculated the areas under the curve 
(AUC) for the receiver operating curves (ROC) 
for all individual score components and for 
all diff erent prognostic scores. Th e AUCs of 
a) the best-performing individual score com-
ponent, b) the best-performing score, c) the 
original ICH score, d) GCS, and e) our opti-
mized logistic regression model were tested 
against each other. Th e Youden index (J) was 
calculated to determine the optimal cut-off 
points and, further, the sensitivity, specifi city, 
positive predictive value (PPV), and negative 
predictive value (NPV) of the selected scores. 
In addition, we created a bivariate correlation 
matrix and used Spearman’s ρ and tolerance as 
analyses of collinearity to measure the relative 
independence of the diff erent score compo-
nents. In addition, to test for the goodness of 
fi t in the prognostic models, Hosmer-Leme-
show test was used (results not shown).
Th e analyses were conducted using SPSS 
20 (IBM Corp., Armonk, NY, USA). For the 
statistical diff erences in the AUCs, we used 
Z derived from ROC-kit v.1.0.3 soft ware197 
(http://metz-roc.uchicago.edu/) with non-par-
ametric assumptions and a U-statistic based 
method.198
4.2  Publications II and III
4.2.1  Patients
For these two publications, we augmented the 
data from publication I with additional data 
from the neurosurgical department. Patients 
between January 2005 and March 2010 with 
ICD-10 codes I60.8, I61, I67.4, I67.4, I67.5, 
I67.6, I67.7, I67.8, I67.9, I68, I69, Q28.1, 
Q28.2, and Q28.3 were screened to fi nd all 
patients with a spontaneous, non-traumatic, 
non-aneurysmal ICH. 
4.2.2  Imaging studies
Immediately on arrival, all patients under-
went a computerised tomography (CT) and 
if needed, a CT angiography to exclude aneu-
rysms, AVMs, and dural fi stulae. If a tumour 
was suspected, MRI was performed. A neuro-
radiologist reviewed the imaging data. Patients 
with a macrovascular or structural cause for 
the haemorrhage (AVM, dural fi stula, cavern-
ous angioma, or tumour) were then excluded 
from the study. We assessed the haematoma 
location, maximal diameter, and volume. 
ICH volume was calculated using the ABC/2 
method.199 
4.2.3  Surgical treatment
As there are no decisive guidelines on the sur-
gical treatment of ICH, indications for surgery 
were not guideline- or protocol-based. Neu-
rosurgical treatment was individually con-
sidered in those patients who presented with 
a large ICH, declining level of consciousness, 
obstructive hydrocephalus, or imminent her-
niation, and were still considered salvageable. 
ICH evacuation was carried out using stand-
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ard microneurosurgical techniques through a 
small open craniotomy (or craniectomy in the 
posterior fossa) under a high-magnifi cation 
surgical microscope. We did not use mini-in-
vasive or other experimental techniques. 
Th ose patients with an intracerebellar 
haemorrhage receiving surgical treatment 
underwent a suboccipital paramedian or 
midline craniotomy and the haematoma was 
evacuated in a standard microneurosurgical 
manner. One patient underwent a primary 
bilateral decompressive craniectomy of the 
posterior fossa and subsequent haematoma 
evacuation. 
If symptomatic hydrocephalus was present, 
patients received an external ventricular drain 
(EVD). EVD was placed at Kocher’s point, 
preferably on the right side. No prophylactic 
antibiotics were used. EVD changes, duration 
of drainage, shunts, and shunt-related compli-
cations were recorded.
In publication II, EVD insertion was not 
considered surgical treatment in patients with 
an intracerebellar haemorrhage, as the mass 
eff ect caused by the haemorrhage in the pos-
terior fossa was considered the real culprit. On 
the other hand, in publication III, both EVD 
or shunt insertion and cerebellar ICH evacu-
ation were considered surgical treatment for 
ICH-related hydrocephalus, where releasing 
the intracranial pressure is usually enough.
4.2.4  Treatment of unconscious 
patients and intensive care
Level of consciousness on arrival was recorded 
on the Glasgow Coma Scale (GCS). Th e GCS 
verbal score for intubated patients was derived 
using the method of Meredith.200 Unconscious 
patients were intubated and mechanically 
ventilated. Propofol was used for sedation of 
intubated patients. Systolic blood pressure 
(BP) was kept under 160 mmHg and con-
trolled with labetalol or clonidine. Electrolyte 
levels and blood gases were routinely ana-
lysed. In case of paralysis of the lower cranial 
nerves and dysphagia, patients received a per-
cutaneous tracheostomy bedside at the ICU. 
Length of ICU and stroke unit treatment were 
recorded.
4.2.5  Characteristics and eff ect 
of surgical treatment on 
mortality 
We fi rst compared the demographic and radi-
ological diff erences and the diff erences in 
treatment between the patients who under-
went haematoma evacuation and those who 
were treated conservatively in the whole 
dataset.  To assess the eff ect of known out-
come modifi ers on long-term mortality, we 
used a Cox proportional hazards model aft er 
checking that the non-informative censoring 
assumption and the proportionality of the 
hazards assumption were met. Log-minus-log 
method was used to assess the proportionality 
assumption.
4.2.6  Intracerebellar haemorrhage
In publication II, based on how they had been 
treated, we divided the patients with a cerebel-
lar ICH into a conservative or surgical treat-
ment group for the analyses. Th e indications 
for surgery were determined case-by-case, 
weighing the haematoma size, declining level 
of consciousness, age, and possible comorbid-
ities. Deeply unconscious patients with signs 
of midbrain or brainstem dysfunction, very 
high age, or severe comorbidities were treated 
medically. All operated patients underwent a 
postoperative computerized tomography (CT) 
scan on the fi rst postoperative day to confi rm 
that brainstem compression and hydrocepha-
lus had relieved. Reoperations were recorded. 
For the cerebellar ICHs, in addition to the 
other radiological variables, we assessed the 
vascular territory of the haematoma. We used 
a three-grade scale by Taneda to classify quad-
rigeminal cistern obliteration.201 A three-grade 
scale by Kirollos was used to classify fourth 
ventricle compression.202 Eff acement of the 
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posterior fossa basal cisterns and obstructive 
hydrocephalus are criteria for  ‘tight posterior 
fossa’, which was used as an indirect marker of 
brainstem compression (Figure 5).139
Figure 5. Example of a ‘tight posterior fossa’ as a 
sign of brainstem compression in an axial brain 
CT.
Figure 6. Stein classifi cation of ICH-related hydrocephalus in an axial brain CT. A) ‘Beginning’, i.e. 
mild hydrocephalus. B) Moderate hydrocephalus. C) Severe hydrocephalus.
4.2.7  Hydrocephalus
We used the Stein classifi cation for hydro-
cephalus.203 Th ey defi ned absence of hydro-
cephalus as a normal ratio of inner and outer 
cerebrospinal fl uid (CSF) spaces without wid-
ening of the temporal horns in the absence of 
signifi cant brain atrophy. ‘Beginning’ hydro-
cephalus (Figure 6A) was defi ned as abnormal 
ratio of inner and outer CSF spaces, with non-
atrophic enlargement of at least one temporal 
horn. ‘Moderate’ hydrocephalus (Figure 6B) 
was defi ned as non-atrophic enlargement of 
one temporal and one frontal horn and sulcal 
eff acement in at least one lobar region (fron-
tal, temporal, parietal, or occipital). Th e defi -
nition for ‘severe’ hydrocephalus (Figure 6C) 
included the criteria for moderate hydroceph-
alus, in addition to sulcal eff acement in two 
regions or bilateral basal cistern compression. 
To record intraventricular haemorrhage sever-
ity, we used the Hallevi IVH score.196
4.2.8  Outcomes
In publication II, we compared the in-hospi-
tal mortality, functional outcome of the med-
ically and surgically treated patients with an 
intracerebellar haemorrhage at hospital dis-
charge, and the impact of the chosen treat-
ment on long-term mortality. In addition, we 
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compared the demographics and radiological 
factors in the surgically and conservatively 
treated patients. We also constructed a bino-
mial logistic regression model to assess the 
eff ect of diff erent demographic and radiolog-
ical factors on poor functional outcome or 
death at discharge (mRS 4-6). 
In publication III, the primary outcome 
was 3-month mortality. We fi rst compared 
the demographic, clinical, and radiological 
diff erences in hydrocephalic and non-hydro-
cephalic patients. Second, we examined only 
those patients who had at least ‘beginning’ 
hydrocephalus. We compared the patients who 
received surgical treatment for their hydro-
cephalus with those who did not to assess the 
eff ect of the treatment on mortality and to 
observe the diff erences in the baseline charac-
teristics in these two groups. As a secondary 
outcome, we compared the 3-month mortality 
between two propensity score-matched groups 
of hydrocephalic patients: those who received 
surgical treatment for their hydrocephalus 
and those who did not. Surgical treatment was 
defi ned as 1) insertion of an EVD or a shunt, 
or 2) evacuation of an intracerebellar haemor-
rhage.
4.2.9  Statistical methods
SPSS 24.0 (IBM Corp., Armonk, NY, USA) 
was used for the statistical analyses. Th e ordi-
nal and continuous variables were tested for 
normality. We used the Kruskal-Wallis and 
Mann-Whitney U tests for skewed and one-
way analysis of variance (ANOVA) for nor-
mally distributed data. Pearson’s chi square 
was used to compare categorical variables 
between the groups. 
In publication II, we used Kaplan-Meier 
analysis to assess the diff erences in long-term 
mortality. For univariate and multivariable 
regression, we used Firth penalised binomial 
regression to discard separation in the stand-
ard maximum likelihood analyses. 
Th e propensity score matching and anal-
ysis were conducted using the PS Match 
3.04 extension package for SPSS by Felix 
Th oemmes (http://arxiv.org/abs/1201.6385). 
For the comparison of surgically and conserv-
atively treated patients in the whole dataset, 
we included age, GCS on arrival, and ICH 
location in the propensity model. We used 
nearest neighbour matching with a calliper of 
0.2 standard deviation (SD) to fi nd matching 
pairs. 
For the surgically and conservatively 
treated patients with hydrocephalus in pub-
lication III, we included age, GCS on arrival, 
haematoma volume, hydrocephalus severity, 
and infratentorial haemorrhage in the pro-
pensity model. We used exact matching on 
infratentorial haemorrhage and hydrocepha-
lus severity, while nearest neighbour matching 
with a calliper of 0.2 SD was used on the other 
variables.
4.3  Publication IV
4.3.1  Patients and treatment
Due to the low incidence in the young, we col-
lected data from a longer time period: from 
January 2000 to March 2010. We used the 
same ICD-10 criteria as in publications II and 
III with one exception: the structural haemor-
rhages related to AVMs, dural fi stulae, cavern-
ous angiomas, and tumours were included in 
the study to characterise the entire spectrum 
of causes of ICH in young adults. Hyperten-
sive microangiopathy was considered the 
cause of ICH if hypertension was present and 
the haemorrhage was deep or infratentorial. 
Structural causes were identifi ed on brain 
imaging and surgical specimens. Other causes 
included cerebral venous thrombosis, vascu-
litis, illicit drug use, eclampsia, liver disease, 
and the syndrome of hemolysis, elevated liver 
enzymes, and low platelet count. 
4.3.2  Statistical methods
Th e analyses were performed using SPSS 20 
(IBM Corp., Armonk, NY, USA). We used 
Pearson’s Chi square for categorical variables, 
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and Mann-Whitney U or Kruskal-Wallis tests 
for skewed continuous variables. Binomial 
logistic regression with the backward likeli-
hood ratio method was used to fi nd the inde-
pendent predictors for 3-month mortality. In 
addition, we constructed a propensity score 
to compare the surgically and conservatively 
treated patients. We included the known out-
come modifi ers: age, sex, NIHSS score, loca-
tion and volume of ICH, structural cause, 
intraventricular blood, hydrocephalus, radi-
ological herniation, and multiple haemor-




5.1  ICH scores 
(Publication I)
In publication I, we discovered 19 diff erent 
prognostic scores for ICH. Th e ICH Func-
tional Outcome Score (ICH-FOS)193 per-
formed best with a small edge over NIHSS for 
3- and 12-month mortality, and for in-hospital 
mortality they performed equally well. 
5.1.1  Prognostic models
We found 19 diff erent prognostic scores and 
models for ICH (Table 1). Many of the score 
shared similar point assignments, refl ecting 
Table 1. Included scores and their derivation cohorts, locations and primary outcomes.








1993 Cincinnati model172 162 No OH, USA (20) 30-day 30-day OHS
1995 Masé equation173 138 No Trieste, Italy (1) 30-day -
1999 Tuhrim equation174 129 Yes New York, NY, USA 
(1)
30-day -
2001 ICH score (oICH)9 152 No San Francisco, CA, 
USA (2)
30-day -
2003 New ICH score (nICH) 
and modifi ed ICH score 
(mICH)187
142 No Hong Kong, China 
(1)
30-day 30-day mRS 0-2
2006 Modifi ed ICH–A and –B 
(mICH-A and –B)189
153 Yes Junin and Bahia 
Bianca, Argentina (2)
30-day 180-day GOS 4-5, 
180-day GOS 2-3
2006 Essen ICH score188 340 No Germany (30) 100-day 100-day BI 95-100, 
100-day BI 0-90
2006 GP on Stage score 
(GPoS)204
995 Yes Asia (14) - Discharge mRS 5-6
2007 ICH grading scale (ICH-
GS)205





2008 FUNC score194 418 Yes Boston, MA, USA (1) - 90-day GOS 4-5
2008 Cho’s MICH score206 226 Yes Taichung, Taiwan (1) 180-day 180-day GOS 4-5, 
180-day BI 55-100
2008 ICH outcome score 
(ICHOS)192
107 No Taoyan, Taiwan (1) 30-day -
2009 Simplifi ed ICH score 
(sICH)190
293 No Taichung, Taiwan (1) 30-day -
2011 Landseed ICH score 
(LSICH)191
285 No Taoyan, Taiwan (1) In-hospital Discharge BI < 40
2012 ICH index (ICHI)149 227 No Chongqing, China (1) In-hospital -
2013 ICH Functional 
Outcome Score (ICH-
FOS)193
1953 No China (132) - 1-year mRS 3-6
2013 Get with the guidelines 
(GWTG) Stroke score168
~6000 Yes USA (1046) In-hospital -
the original ICH score (Table 2A-C). Addi-
tionally, fi ve scores provided a formula for 
the probability of death or survival (Table 3).9 
For this publication, we used data from the 
original Helsinki ICH study, collected from 
the neurological department at our institute 
between January 2005 and March 2010. Of the 
1013 consecutive patients with a spontaneous 
ICH in the database, 131 were excluded due 
to missing data, leaving 882 patients for the 
analyses. Th e observed in-hospital mortal-




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2B. Some of the scores also included dialysis treatment, body temperature or blood glucose.
sICH nICH
GCS 14-15 1 NIHSS 0-10 0
13-9 2 11-20 1
5-8 3 21-40 2
3-4 4 Temperature ≤ 36 °C 0
Age < 80 1 > 36 °C 1
≥ 80 2 Pulse pressure ≥ 60 mmHg 0
Hypertension no 1 < 60 mmHg 1
yes 2 IVH no 0
Blood glucose ≤ 11 mmo/l 1 yes 1
> 11 mmol/l 2 SAH no 0
Dialysis no 1 yes 1
yes 2 Total score   0-6
Total score   5-12
Table 2C. Th e GWTG-Stroke Risk Score was designed for all stroke types and it includes also variables 















Mode of arrival Private transport 0
Already in hospital 8
Ambulance from scene 9
Gender Female 0
Male 2
AF present no 0
yes 5
History of stroke/TIA yes 0
no 2
Previous CHD no 0
yes 4
Peripheral vascular disease no 0
yes 3
History of dyslipidemia yes 0
no 3
Arrival 7am-5pm Mon to Fri yes 0
no 1




Total score   0-120
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Table 3. Five of the scores were based on a mathematical formula.
Score Formula
Tuhrim equation for 30-day mortality174 p = e^z/(1+e^z) 
z = (-3.3125 + 0.018 * size of ICH in ml + 0.0979 * size of 
intraventricular haemorrhage (IVH) in ml + 0.5832 (if pulse 
pressure > 85mmHg) + 2.27859 (if GCS < 9) – 0.9567 (if 
hydrocephalus present)
ICHI index for in-hospital mortality149 p = age/10 + glucose in mmol/l + white blood cell count in 
10*9/l – GCS
GWTG score for in-hospital mortality168 p = 1/(1 + exp(5.949803 - 0.066087*GWTG total score))
GPoS  probability of mRS 5-6 at discharge204 p = e^z/(1+e^z)
z = 2.7915 + 0.8637 (if temp ≥ 37.8°C) + 0.8992 (if ICH 
volume ≥ 30 ml) + 0.9294 (if IVH present) – 0.3653 * GCS
Masé model  survival probability at 30 
days173
p = 1/(1+e^0.5242 – 0.2521 * GCS + 1.7536 (if IVH present) 
+ 0.0249 * VOL)
VOL = 2.7 if ICH volume < 8.3cm3, 11.4 if volume 8.3-20.4 
cm3, 28.8 if volume 20.5-47.7 cm3 and 76.8 if volume > 47.7 
cm3
5.1.2  Association with mortality
Th e majority of the score components were 
associated with mortality in univariate anal-
yses (Tables 4 and 5). Of the continuous var-
Results
iables, only “Systolic blood pressure”, “Pulse 
pressure”, and “Temperature” were not asso-
ciated with mortality. Th us, nearly all of these 
factors had prognostic importance. 
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Table 4. Demographics of the study population: dichotomous score components and their associa-
tion with mortality. Comorbidities were classifi ed as presence of any major cardiovascular, renal, 
pulmonary, or metabolic conditions such as end-stage cancer, New York Heart Association (NYHA) 
class IV cardiac failure or coronary heart disease, dialysis-dependent renal insuffi  ciency, hepatic cirr-









Male (n=508) 136 (26.8%) 171 (33.7%) 192 (37.8%)
Female (n=374) 72 (19.3%) 102 (27.3%) 119 (31.8%)
Cortical location 0.510
Yes (n=338) 76 (22.5%) 96 (28.4%) 115 (34.0%)
No (n=554) 132 (24.3%) 177 (32.5%) 196 (36.0%)
Deep (including thalamic) 
location
0.1291
Yes (n=483) 122 (25.3%) 164 (34.0%) 182 (37.7%)
No (n=399) 86 (21.6%) 109 (27.3%) 129 (32.3%)
Infratentorial location < 0.001
Yes (n=123) 49 (39.8%) 55 (44.7%) 56 (45.5%)




Yes (n=354) 143 (40.4%) 186 (52.5%) 198 (55.9%)
No (n=528) 65 (12.3%) 87 (16.5%) 113 (21.4%)
Subarachnoid haemorrhage 0.076
Yes (n=113) 46 (40.7%) 61 (54.5%) 69 (61.1%)
No (n=769) 162 (21.1%) 212 (27.6%) 242 (31.5%)
Hydrocephalus < 0.001
Yes (n=123) 83 (67.5%) 95 (77.2%) 96 (78.0%)
No (n=759) 125 (16.5%) 178 (23.5%) 215 (28.3%)
Dialysis 0.631
Yes (n=14) 4 (28.6%) 5 (35.7%) 5 (35.7%)
No (n=868) 204 (23.5%) 268 (30.9%) 306 (35.3%)
Comorbidities < 0.001
Yes (n=384) 102 (26.6%) 139 (36.2%) 162 (42.2%)
No (n=498) 106 (21.3%) 134 (26.9%) 149 (29.9%)
Pre-ICH cognitive defi cit < 0.001
Yes (n=40) 14 (35.0%) 21 (52.5%) 26 (65.0%)
No (n=842) 194 (23.0%) 252 (29.9%) 285 (33.8%)
Atrial fi brillation < 0.001
Yes (n=90) 34 (37.8%) 40 (44.4%) 45 (50.0%)
No (n=792) 174 (22.0%) 233 (29.4%) 266 (33.6%)
Previous stroke or TIA 0.103
Yes (n=144) 38 (26.4%) 49 (34.0%) 59 (41.0%)
No (n=738) 170 (23.0%) 224 (30.4%) 252 (34.1%)
Peripheral artery disease 0.032
Yes (n=15) 7 (46.7%) 7 (46.7%) 8 (53.5%)
No (n=867) 201 (23.2%) 266 (30.7%) 303 (34.9%)
Coronary heart disease < 0.001
Yes (n=122) 37 (30.3%) 54 (44.3%) 63 (51.6%)
No (n=760) 171 (22.5%) 219 (28.8%) 248 (32.6%)
Dyslipidemia 0.292
Yes (n=177) 33 (18.6%) 51 (28.8%) 57 (32.2%)
No (n=705) 175 (24.8%) 222 (31.5%) 254 (36.0%)
Aft er-hours arrival 0.638
Yes (n=524) 121 (23.1%) 160 (30.5%) 182 (34.7%)
No (n=358) 87 (24.3%) 113 (31.6%) 129 (36.0%)
Arrival by ambulance < 0.001
Yes (n=774) 200 (25.8%) 264 (34.1%) 301 (38.9%)
No (n=108) 8 (7.4%) 9 (8.3%) 10 (9.3%)
Arrival by other than ER 0.911
Yes (n=13) 4 (30.8%) 5 (38.5%) 5 (38.5%)
No (n=869) 204 (23.5%) 268 (30.8%) 306 (35.2%)
Arrival by private transport < 0.001
Yes (n=95) 4 (4.2%) 4 (4.2%) 5 (5.3%)
No (n=787) 204 (25.9%) 269 (34.2%) 306 (38.9%)
Diabetes 0.321
Yes (n=125) 32 (25.6%) 41 (32.8%) 50 (40.0%)
No (n=757) 176 (23.2%) 232 (30.6%) 261 (34.5%)
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Table 5. Demographics of the study population: continuous score components and their prognostic 
performance.






Age (years) 68 (58-78) 0.559 (0.515-0.604) 0.633 (0.593-0.674) 0.658 (0.620-0.696)
ICH volume (ml) 9.70 (3.76-26.1) 0.759 (0.720-0.799) 0.761 (0.726-0.797) 0.757 (0.723-0.791)
GCS 14 (11-15) 0.825 (0.790-0.860) 0.790 (0.755-0.824) 0.767 (0.732-0.801)
NIHSS 11 (4-19) 0.852 (0.821-0.882) 0.848 (0.820-0.876) 0.826 (0.797-0.855)
NIHSS alertness 0 (0-1) 0.813 (0.776-0.849) 0.778 (0.742-0.814) 0.753 (0.717-0.789)
Graeb score 0 (0-4) 0.733 (0.690-0.776) 0.743 (0.705-0.781) 0.717 (0.680-0.755)
Temperature (°C) 36.7 (36.3-37.2) 0.584 (0.534-0.633) 0.582 (0.539-0.626) 0.559 (0.516-0.601)
Blood glucose 
(mmol/l)
7.2 (6.1-9.1) 0.686 (0.646-0.726) 0.663 (0.625-0.701) 0.645 (0.608-0.683)
Systolic blood 
pressure (mmHg)
172 (149-193) 0.541 (0.493-0.590) 0.533 (0.490-0.576) 0.516 (0.476-0.557)
Pulse pressure 
(mmHg)
79 (63-96) 0.545 (0.496-0.593) 0.546 (0.502-0.589) 0.539 (0.497-0.580)
5.1.3  Prognostic performance
In the receiver operating curve (ROC) anal-
yses of the individual score components, the 
National Institutes of Health Stroke Scale 
(NIHSS) had the highest area under curve 
(AUC) at every time point (Table 6). In the 
ROC analyses of the diff erent scores, the ICH 
Functional Outcome Score (ICH-FOS)193 per-
formed best. Th e experimental regression 
model produced good AUC values for all time 
points (Table 7). 
Table 6. Prognostic performance of the diff erent scores.






Cincinnati model172 0.7898 (0.754-0.825) 0.7664 (0.734-0.799) 0.7393 (0.708-0.771)
Masé equation173 0.8570 (0.827-0.888) 0.8480 (0.819-0.877) 0.8230 (0.793-0.853)
Tuhrim equation174 0.6580 (0.611-0.705) 0.6293 (0.587-0.672) 0.6187 (0.578-0.672)
ICH score (oICH 9 0.8414 (0.811-0.872) 0.8454 (0.818-0.873) 0.8163 (0.787-0.846)
New ICH score (nICH)187 0.8497 (0.821-0.879) 0.8661 (0.841-0.891) 0.8453 (0.819-0.872)
Modifi ed ICH Score (mICH)187 0.7931 (0.759-0.827) 0.8010 (0.770-0.832) 0.7881 (0.757-0.819)
Modifi ed ICH–A (mICH-A)189 0.8498 (0.818-0.882) 0.8584 (0.831-0.886) 0.8392 (0.811-0.867)
Modifi ed ICH-B (mICH-B)189 0.8500 (0.818-0.882) 0.8574 (0.830-0.885) 0.8381 (0.810-0.866)
Essen ICH score188 0.8387 (0.807-0.870) 0.8539 (0.826-0.882) 0.8470 (0.820-0.875)
GP on Stage score (GPoS)204 0.8520 (0.821-0.884) 0.8370 (0.808-0.867) 0.8100 (0.799-0.841)
ICH grading scale (ICH-GS)205 0.8429 (0.811-0.875) 0.8419 (0.814-0.870) 0.8156 (0.786-0.845)
FUNC score194 0.8086 (0.771-0.843) 0.8126 (0.781-0.845) 0.7858 (0.753-0.818)
Cho’s MICH score206 0.8503 (0.820-0.880) 0.8395 (0.811-0.868) 0.8125 (0.783-0.842)
ICH outcome score (ICHOS)192 0.7570 (0.716-0.798) 0.765 (0.729-0.801) 0.7620 (0.728-0.796)
Simplifi ed ICH score (sICH)190 0.7897 (0.754-0.826) 0.7781 (0.745-0.812) 0.7654 (0.733-0.798)
Landseed ICH score (LSICH)191 0.8280 (0.794-0.862) 0.8170 (0.785-0.849) 0.7890 (0.757-0.822)
ICH index (ICHI)149 0.7858 (0.751-0.821) 0.7688 (0.735-0.803) 0.7462 (0.712-0.780)
ICH Functional Outcome Score 
(ICH-FOS)193
0.8661 (0.838-0.896) 0.8802 (0.855-0.906) 0.8642 (0.838-0.891)
Get with the guidelines (GWTG) 
Stroke score168
0.8540 (0.824-0.883) 0.860 (0.833-0.887) 0.8450 (0.818-0.872)
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Derivation cohort 0.9090 (0.875-0.944) 0.9030 (0.871-0.934) 0.8830 (0.849-0.917)
Validation cohort 0.8350 (0.792-0.879) 0.8660 (0.830-0.902) 0.8660 (0.830-0.901)
All patients 0.8730 (0.844-0.901) 0.8900 (0.867-0.913) 0.8740 (0.850-0.899)
5.1.4  Comparison of scores’ 
performance
We then compared the AUC results of the 
best-performing single score component 
(NIHSS), the best-performing score (ICH-
FOS), GCS, the original ICH score, and our 
regression model against each other. For 
in-hospital mortality, no signifi cant diff er-
ences emerged between NIHSS, GCS, or 
ICH-FOS scores. Th e original ICH score was 
equal to NIHSS and GCS, but inferior to the 
ICH-FOS score. For 3- and 12-month mortal-
ity, ICH-FOS was the best performer, with a 
statistically signifi cant diff erence to the other 
tested scores, with a minor edge over NIHSS 
(Table 8). Th e optimal cut-off  for ICH-FOS 
was 8 points for in-hospital and 3-month mor-
tality, and 7 points for 12-month mortality. 
For NIHSS, the optimal cut-off  for in-hospital 
mortality was 14 points.
Table 8. Statistical signifi cance of the diff erences in prognostic performance at the three time points. 
Th e results for the regression model are presented for all patients.
NIHSS GCS oICH 9 ICH-FOS 193
In-hospital mortality p p p p
 GCS 0.3827 - - -
 oICH 0.4858 0.5997 - -
 ICH-FOS 0.1522 0.1600 0.0092 -
 Regression model (all patients) 0.1669 0.1037 0.0316 0.7058
3-month mortality
 GCS 0.0411 - - -
 oICH 0.8786 0.0506 - -
 ICH-FOS 0.0003 0.0008 0.0002 -
 Regression model (all patients) 0.0020 0.0003 <0.0001 0.6241
12-month mortality
 GCS 0.0366 - - -
 oICH 0.4928 0.0854 - -
 ICH-FOS <0.0001 0.0003 <0.0001 -
 Regression model (all patients) <0.0001 <0.0001 <0.0001 0.2588
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5. 2  Characteristics and 
effect of surgical 
treatment on mortality 
(Publications II and III)
5.2.1  Demographics and 
presentation
Th e data used in publications II and III 
included 1075 patients with a non-traumatic, 
non-aneurysmal ICH between January 2005 
and March 2010 presenting at the neurologi-
cal and neurosurgical emergency rooms at our 
institute. Patients’ mean age was 67.4 years, 
with a slight male predominance. A history 
of atrial fi brillation was found in 13.7% of 
patients, 62.3% had hypertension, and 13.3% 
were diabetic (Table 9). Th e mean haematoma 
volume was 25.5 ml, and the patients were in 
rather good condition, with a median GCS of 
14. Th e majority of the haemorrhages were 
deep (basal ganglia or thalamic) ICHs (Table 
10). All but three patients (99.7%) underwent 
a CT scan, CT angiography was performed in 
295 patients (27.4%), MRI in 143 (13.3%), and 
DSA in 12 (1.1%) of the patients.








Age in years, mean (95% CI) 67.4 (66.6-68.2) 68.1 (67.3-69) 60.6 (58.3-62.9) < 0.001
Male gender, n (%) 618 (57.5%) 562 (58.1%) 56 (51.9%) 0.212
Atrial fi brillation, n (%) 147 (13.7%) 138 (14.3%) 9 (8.3%) 0.088
Hypertension, n (%) 670 (62.3%) 621 (64.2%) 49 (45.4%) < 0.001
Diabetes, n (%) 143 (13.3%) 136 (14.1%) 7 (6.5%) 0.028
Liver disease, n (%) 43 (4.0%) 38 (3.9%) 5 (4.6%) 0.725
Heavy drinking, n (%) 151 (14.0%) 135 (14.0%) 16 (14.8%) 0.809
Warfarin, n (%) 155 (14.4%) 143 (14.8%) 12 (11.1%) 0.302
Any antiplatelet drug, n (%) 266 (24.8%) 252 (26.1%) 14 (13.0%) 0.003
Statins, n (%) 195 (18.1%) 180 (18.7%) 15 (13.9%) 0.227
mRS at arrival, median (IQR) 0 (0), range 0-5 0 (0), range 0-5 0 (0), range 0-3 0.001








GCS at arrival, median (IQR) 14 (9-15) 14 (10-15) 12 (4-14) < 0.001
Systolic BP at arrival, mean 
(95% CI)
174 (172-176) 173 (171-175) 180 (174-187) 0.052
Haematoma volume in ml, 
mean (95% CI)
25.5 (23.4-27.6) 22.3 (20.3-24.3) 52.0 (44.6-59.5) < 0.001
Maximal diameter in mm, 
mean (95% CI)
41.8 (40.6-43.1) 39.9 (38.5-41.1) 57.6 (54.5-60.7) < 0.001















































5.2.2  Diff erences in surgically and 
conservatively treated patients
Th e operated patients were younger and had 
less comorbidities such as hypertension and 
diabetes. No statistically signifi cant diff erences 
were present in the use of warfarin, but the 
operated patients less oft en used antiplatelet 
drugs. Operated patients’ premorbid func-
tional status was statistically better (p=0.001), 
although the mean mRS in both groups was 
0 with an interquartile range of 0 (Table 9). 
Operated patients had signifi cantly lower 
GCS on arrival, and their haematoma volumes 
and maximal haematoma diameters were sig-
nifi cantly larger as well. Th ey had a greater 
incidence of intraventricular haemorrhage 
and hydrocephalus. In operated patients, the 
haemorrhages were less likely to be located 
in the deep (basal ganglia or thalamus) area 
(p=0.001) and more likely to be in the cere-
bellum (p < 0.001) (Table 10). For these anal-
yses, we classifi ed all haemorrhages extending 
to the brainstem as brainstem haemorrhages, 
and all haemorrhages extending to basal gan-
glia (but not to the brainstem) as basal ganglia 
haemorrhages due to the functional conse-
quences of neuronal damage in these areas. 
In publication II, we allowed haemorrhages 
extending to multiple areas to be classifi ed in 
multiple locations. In publication III, haemor-
rhages situated mainly in the cerebellum were 
classifi ed as intracerebellar hemorrhages.
5.2.3  Treatment
Operated patients were more oft en treated in 
the ICU or acute stroke unit (p<0.001), with 
a median duration of 6 days (versus 1 day in 
conservatively treated patients). In addition, 
operated patients had greater frequencies of 
ventricular drainage and tracheostomy. Total 
length of hospital stay before in-hospital death, 
referral to a rehabilitation facility, or discharge 
to home was also signifi cantly longer in sur-
gically treated patients (p < 0.001) (Table 11).








Ventricular drainage, n (%) 48 (4.5%) 20 (2.1%) 28 (25.9%) < 0.001
Tracheostomy, n (%) 55 (5.1%) 18 (1.9%) 37 (34.3%) < 0.001
Treated in ICU or acute stroke 
unit, n (%)
593 (55.2%) 496 (51.3%) 97 (89.8%) < 0.001
ICU and acute stroke unit days, 
median (IQR)
1 (0-4) 1 (0-3) 6 (3-10) < 0.001
Hospital days, median (IQR) 9 (3-14) 8 (3-14) 13 (7-21) < 0.001
5.2.4  Short- and long-term 
mortality
We did not observe a signifi cant diff erence in 
the functional outcome at hospital discharge 
between surgically and conservatively treated 
patients (p=0.155). In addition, no signifi -
cant diff erences emerged in in-hospital or 
12-month mortality between surgically and 
conservatively treated patients. Th e 3-month 
mortality was signifi cantly lower in surgically 
treated patients, but the diff erence disappeared 
during the follow-up. Mean follow-up was sig-
nifi cantly longer in surgically treated patients 
(p < 0.001) (Table 12).
In Kaplan-Meier analysis of long-term 
mortality between surgically and conserva-
tively treated patients, the operated patients’ 
long-term survival was signifi cantly better (p 
= 0.005) with a median survival time of 10.22 
years (95% CI 6.73-13.71) versus 4.62 years 
(95% CI 3.69-5.55) (Figure 7A). 
When considering only the propensity 
score-matched patients, the diff erence was 
even more pronounced (p < 0.001) with a 
median survival time of 8.95 years (95% CI 












Mortality in hospital, n (%) 273 (25.4%) 253 (26.2%) 20 (18.5%) 0.081
mRS at discharge, survivors, 
median (IQR)
4 (3-5) 4 (3-5) 5 (4-5) 0.155
Mortality at 3 months, n (%) 393 (36.6%) 324 (33.6%) 24 (22.2%) 0.017
Mortality at 12 months, n (%) 384 (32.6%) 359 (37.2%) 34 (31.5%) 0.242
Follow-up length in years, 
mean (95% CI)
2.41 (2.26-2.55) 2.26 (2.11-2.40) 3.79 (3.14-4.44) < 0.001
Figure 7A. Diff erences in long-term mortality of all surgically and conservatively treated patients. 






In the Cox proportional hazards model, 
the proportionality assumption was met with 
all other variables (age group, GCS on arrival, 
and ICH volume) except ICH location, which 
was therefore omitted from the regression 
model. In univariate regression, lower GCS 
on admission, increasing age, greater haemat-
oma volume, and haemorrhage location in 
the brainstem were associated with a greater 
risk of death in long-term follow-up (Figure 
8A-C). In multivariable regression, the results 
did not change, with age over 80 years being 
associated with a 9-fold risk of death (Table 13 
and Figure 8D).
Figure 8A. Survival in diff erent age groups (all patients), univariate Cox regression.





C. Survival in groups with diff erent ICH volume (all patients), univariate Cox regression.





Table 13. Univariate and multivariable results of the Cox proportional hazards model on long-term 
mortality aft er ICH.
Variable Categories Multivariable HR 
(95% CI)
p Univariate HR (95% 
CI)
p
GCS 13-15 1 (reference) 1 (reference)
9-12 1.858 (1.45-2.38) < 0.001 2.197 (1.73-2.79) < 0.001
3-8 3.244 (2.59-4.06) < 0.001 4.78 (3.92-5.83) < 0.001
ICH volume < 10 ml 1 (reference) 1 (reference)
10-29 ml 1.414 (1.11-1.80) 0.005 1.493 (1.19-1.88) 0.001
30-49 ml 1.965 (1.46-2.64) < 0.001 2.299 (1.76-3.00) < 0.001
50-69 ml 2.476 (1.73-3.54) < 0.001 3.070 (2.19-4.31) < 0.001
> 70 ml 3.431 (2.54-4.63) < 0.001 4.743 (3.62-6.21) < 0.001
Age group < 50 years 1 (reference) 1 (reference)
50-64 years 2.796 (1.73-4.51) < 0.001 2.779 (1.72-4.49) < 0.001
65-79 years 4.870 (3.07-7.74) < 0.001 4.371 (2.75-6.94) < 0.001
> 80 years 8.814 (5.49-14.16) < 0.001 8.649 (5.38-13.9) < 0.001
Table 14. Mortality in the diff erent locations at diff erent time points.
In-hospital mortality, n (%) 3-month mortality, n (%) 12-month mortality, n (%)
Cortical 61 (18.8%) 81 (25.0%) 100 (30.9%)
Deep 141 (24.6%) 187 (32.6%) 206 (35.9%)
Brainstem 46 (71.9%) 48 (75.0%) 48 (75.0%)
Cerebellum 22 (21.2%) 27 (26.0%) 34 (32.7%)
Intraventricular 3 (33%) 5 (55.6%) 5 (55.6%)
5.3  Intracerebellar 
haemorrhage 
(Publication II)
In publication II, we showed that no signifi -
cant diff erences existed in either in-hospital 
nor long-term mortality between surgically 
and conservatively treated patients, although 
a non-signifi cant trend towards better sur-
vival in the surgical treatment group emerged. 
However, operated patients more oft en 
remained in poor clinical condition.
5.3.1  Demographics and 
presentation
Of the 1075 patients with a non-traumatic, 
non-aneurysmal ICH, 114 (10.9%, 47 female) 
presented with an intracerebellar haemor-
rhage. Th irty-eight patients (33.3%) were 
operated on and 76 (66.7%) were managed 
conservatively. Of the 10 patients with a 
mainly intracerebellar haemorrhage extend-
ing to the brainstem, one underwent surgical 
treatment and nine were treated conserva-
tively.
As in analyses including all patients with 
an ICH, those patients with an intracerebel-
lar ICH who underwent surgical treatment 
were younger and had less atrial fi brillation 
and hypertension than conservatively treated 
patients (Table 15). However, their clinical 
condition on arrival was signifi cantly worse. 
Surgically treated patients had larger ICHs and 
more frequent hydrocephalus, quadrigeminal 
cistern eff acement, fourth ventricle obstruc-
tion, and brainstem compression (Table 16). 
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Table 15. Demographics and comorbidities in surgically and medically treated patients with an 
intracerebellar haemorrhage.
Medical treatment (n=76) Surgical treatment (n=38) p
Male gender, n (%) 45 (59.2%) 22 (57.9%) 0.893
Age in years, mean (95% CI) 71.6 (68.9-74.4) 61.7 (57.6-65.8) < 0.001
Atrial fi brillation 16 (20.8%) 0 0.03
Hypertension 54 (71.1%) 18 (47.4%) 0.013
Diabetes 17 (22.4%) 3 (7.9%) 0.055
Liver disease 5 (6.6%) 2 (5.4%) 0.808
Heavy drinking 7 (13.5%) 5 (19.2%) 0.506
Warfarin 12 (15.8%) 3 (7.9%) 0.24
Any antiplatelet drug 20 (26.7%) 7 (18.4%) 0.332
Statins 12 (16.2%) 5 (13.2%) 0.669
mRS at arrival, median (IQR) 0 (0) 0 (0) 0.296
Table 16. Clinical and radiological characteristics on arrival in surgically and medically treated 
patients with an intracerebellar haemorrhage.
Medical treatment (n=76) Surgical treatment (n=38) p
GCS on arrival, median (IQR) 15 (8-15) 6 (3-14) < 0.001
Systolic BP on arrival, mean (95% 
CI)
174 (166-182) 188 (174-202) 0.065
Haematoma volume in ml, mean 
(95% CI)
12.7 (9.9-15.5) 30.4 (25.3-35.4) < 0.001





































Brainstem compression, n (%) 24 (31.6%) 35 (92.1%) < 0.001
5.3.2  Treatment of patients with an 
intracerebellar haemorrhage
Of surgically treated patients, 92.1% were 
treated in the ICU or acute stroke unit for at 
least 24 hours, compared with 55.3% in the 
conservatively treated group (p < 0.001). Th e 
surgically treated patients stayed longer in the 
ICU or stroke unit (median 8 days [IQR 5-11] 
versus 1 day [0-4], p < 0.001) and their total 
hospital stay (before in-hospital death, refer-
ral to a rehabilitation facility or discharge to 
home) was also longer (median 16 days [IQR 
10-26] versus 7 days [2-13], p < 0.001). Th e fre-
quency of tracheostomies was also signifi cantly 
greater in surgically treated patients (63.2%, 
24 patients) than in conservatively managed 
patients (2.6%, 2 patients) (p < 0.001). 
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5.3.3  Outcomes and outcome 
modifi ers
In-hospital mortality was 31.6% (24 patients) 
in medically and 18.4% (7 patients) in surgi-
cally treated patients, but the diff erence was 
not signifi cant (p = 0.137). Long-term mor-
tality was 50% in medically and 47.4% in 
surgically treated patients (p = 0.791). Mean 
follow-up length was 27.3 months (95% CI 
20.7-33.8 months) in medically and 45.7 
months (95% CI 31.9-59.6 months) in surgi-
cally treated patients. Th e diff erence was sig-
nifi cant (p=0.005). In Kaplan-Meier analy-
sis, we did not fi nd a signifi cant diff erence in 
long-term mortality between the treatment 
groups (p=0.184), with a median survival 
time of 4.64 years (95% CI 1.67-7.62 years) 
in the conservative treatment group and 8.95 
years (95% CI 0.54-17.36 years) in the surgi-
cal treatment group (Figure 9). However, the 
clinical outcome of the surviving patients at 
hospital discharge was signifi cantly worse in 
the surgically treated group – the median mRS 
with interquartile ranges was 4 (3-4) in the 
medically and 5 (4-5) in the surgically treated 
group (Figure 10). Th e diff erence was signifi -
cant (p<0.001).
To assess the eff ect of diff erent factors on 
poor outcome or death (mRS 4-6) at hospi-
tal discharge, we constructed a multivariable 
regression model (Table 17). GCS <8 (OR 
366.1, 95% CI 1.84-3270000, p = 0.023) and 
age group 65-79 years (OR 113.2, 95% CI 2.27-
12700000, p = 0.012) were associated with 
poor outcome. Due to small sample size, some 
of the confi dence intervals were unrealistic. 
Figure 9. Kaplan-Meier analysis of long-term mortality in the two treatment groups. Th e diff erence 
was insignifi cant (p=0.184).
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Table 17. Results of univariate logistic regression on poor functional outcome and mortality 
(modifi ed Rankin Scale 4-6).
Variable Odds Ratio 95% CI p
Age group Under 50 reference
50-64 1.647 0.064-626 0.765
65-79 113.2 2.27-12700000 0.012
Over 80 48.04 0.812-6200000 0.067
GCS at arrival 13-15 reference
8-12 9.767 0.345-2180 0.175
3-7 366.1 1.84-3270000 0.023
Ventricular blood 11.31 0.838-3530 0.073
Brainstem compression 6.586 0.293-3230 0.236
Volume > 10 ml 0.399 0.017-5.6 0.496
Diameter > 3 cm 3.145 0.337-52.9 0.317
Extension to brainstem 5.094 0.045-5550 0.51
Hydrocephalus No reference
‘Beginning’ 5.589 0.401-2280 0.211
‘Moderate’ 8.82 0.441-799 0.167
‘Severe’ 90.83 0.853-1580000 0.06
Fourth ventricle Open reference
Compressed 3.939 0.51-51.5 0.202
Blocked 0.3738 0-17.2 0.631
Quadrigeminal cistern Open reference
Compressed 1.068 0.063-100 0.965
Blocked 1.635 0.008-2400 0.851
Surgical treatment 1.98 0.098-1010 0.662
Figure 10. Functional outcome of surviving patients (n=30 in operative group, n=53 in conservative 




5.4  ICH-related 
hydrocephalus 
(Publication III)
In publication III, we showed that hydroce-
phalic patients were in signifi cantly worse 
clinical condition, had larger ICHs, and had 
more frequent intraventricular haemorrhage 
than patients who did not have hydrocepha-
lus. In-hospital and 3-month mortality were 
lower in those patients who received surgical 
treatment for hydrocephalus. In a propensity 
score-matched comparison, surgical treatment 
of hydrocephalus was associated with a 50% 
lower 3-month mortality than non-surgical 
treatment.
5.4.1  Demographics and 
presentation
Of the 1075 patients, 105 patients (9.8%) had 
‘beginning’, 112 (10.4%) ‘moderate’, and 79 
(7.3%) ‘severe’ hydrocephalus on the Stein clas-
sifi cation. No diff erences were present in the 
age or gender distribution between non-hy-
drocephalic and hydrocephalic patients, but 
patients with abnormal ventricular size were 
in signifi cantly worse clinical condition, had 
larger haematomas, and had more frequent 
IVH. Th e haemorrhages were more oft en sit-
uated in the cerebellum, basal ganglia, and 
brainstem and less oft en in the lobar region 
(Table 18). Compared with non-hydrocephalic 
patients, the in-hospital and 3-month mortali-
ties were higher in hydrocephalic patients, and 
they were left  in a signifi cantly worse clinical 
condition aft er a signifi cantly longer period 
in the hospital before in-hospital death, trans-
fer to a rehabilitation facility/hospice, or dis-
charge to home (Table 19).
Table 18. Diff erences between ICH patients with normal ventricular size and hydrocephalus. Pa-
tients with ‘beginning’ hydrocephalus on the Stein classifi cation were defi ned as hydrocephalic. 
Patients were included in multiple location categories if the haematoma extended to multiple territo-
ries.
Variable No hydrocephalus (n=777) Hydrocephalus (n=298) p
Age in years, mean (95% CI) 67.7 (66.7-68.6) 66.7 (65.1-68.2) 0.26
Female gender, n (%) 329 (42.3%) 128 (43%) 0.856
GCS on arrival, median (IQR) 15 (12-15) 7 (3-14) < 0.001
Systolic BP in mmHg, mean (95% CI) 173 (171-176) 175 (171-180) 0.481
ICH volume in ml, mean (95% CI) 17.3 (15.7-19) 46.1 (40.7-51.4) < 0.001
Lobar, n (%) 572 (73.6%) 126 (42.3%) < 0.001
Basal ganglia, n (%) 131 (16.9%) 69 (23.2%) 0.018
Brainstem, n (%) 38 (4.9%) 26 (8.7%) 0.017
Cerebellum, n (%) 34 (4.4%) 79 (23.5%) < 0.001
Only IVH, n (%) 2 (0.3%) 7 (2.3%) 0.001
Intraventricular blood, n (%) 217 (21.7%) 258 (86.6%) < 0.001
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Table 19. Treatment and outcomes in patients with and without hydrocephalus.
Variable No hydrocephalus (n=777) Hydrocephalus (n=298) p
Haematoma evacuation (all 
locations), n (%)
44 (5.7%) 64 (21.5%) < 0.001
Hospital days, median (IQR) 9 (4-15) 5 (1-13) < 0.001
Mortality in hospital, n (%) 110 (14.2%) 163 (54.7%) < 0.001
mRS at discharge, median (IQR) 4 (2-5) 5 (4-5) < 0.001
Mortality at 3 months, n (%) 159 (20.5%) 189 (63.4%) < 0.001
5.4.2  Surgical treatment for 
hydrocephalus
We then examined the 298 hydrocephalic 
patients in detail. In total, 61 patients (20.5%) 
received surgical treatment for hydrocepha-
lus, i.e. either received an EVD (n=47, 77%) 
and/or underwent cerebellar ICH evacua-
tion (n=42, 68.9%). Th e surgically treated 
patients were younger, their premorbid func-
tional status was slightly better, and they had 
smaller haemorrhages. No statistically signif-
icant diff erences existed in clinical status on 
arrival. Th e patients who received surgical 
treatment for hydrocephalus had more oft en 
cerebellar haemorrhages, and less oft en corti-
cal and deep hemispheric haemorrhages. Th ey 
also had lower median IVH scores and more 
oft en moderate or severe hydrocephalus. Due 
to their dismal clinical situation, 58 patients 
(79%) with severe hydrocephalus did not 
receive surgical treatment (Table 20).
Table 20. Diff erences in hydrocephalic patients who did or did not receive surgical treatment for 
hydrocephalus.
Variable No surgical treatment for 
hydrocephalus (n=237)
Surgical treatment for 
hydrocephalus (n=61)
p
Age in years, mean (95% CI) 68.1 (66.4-69.8) 61.1 (57.8-64.5) 0.001
Female gender, n (%) 101 (42.6%) 27 (44.3%) 0.817
mRS before arrival, median (IQR, range) 0 (0-1, range 0-5) 0 (0, range 0-3) 0.014
GCS on arrival, median (IQR) 7 (3-13) 6 (3-14) 0.986
ICH volume in ml, mean (95% CI) 51.2 (44.7-57.6) 26.3 (21.9-30.7) 0.002
Lobar, n (%) 120 (50.6%) 6 (9.8%) < 0.001
Th alamic, n (%) 61 (25.7%) 8 (13.1%) 0.037
Brainstem, n (%) 23 (9.7%) 3 (4.9%) 0.237
Cerebellum, n (%) 29 (12.2%) 41 (67.2%) < 0.001
Only IVH, n (%) 4 (1.7%) 3 (4.9%) 0.137
Intraventricular blood, n (%) 210 (88.6%) 48 (78.7%) 0.043
IVH score, median (IQR) 5 (2-7) 4 (2-5) 0.001













Compared with patients who did not 
receive surgical treatment for hydrocephalus, 
the patients whose hydrocephalus was treated 
surgically underwent haematoma evacuation 
(all locations) more frequently (68.9% vs 9.3%, 
p < 0.001), stayed longer in the ICU or acute 
stroke unit (median 7 days [IQR 3-12] vs 0 
days [0-3], p < 0.001), and had longer hospi-
tal stay (median 16 days [IQR 8-26] vs. 3 days 
[1-8], p < 0.001). 
5.4.3  Outcome aft er surgical 
treatment for hydrocephalus
Compared with patients whose hydrocephalus 
was treated conservatively, those who received 
surgical treatment for hydrocephalus had sig-
nifi cantly lower in-hospital (19.7% vs. 63.7%, 
p < 0.001) and 3-month mortality (27.9% vs. 
72.6%, p < 0.001).  No diff erence existed in 
functional outcome at hospital discharge; it 
was poor in both groups (median 5 [IQR 4-5], 
p=0.206). 
We then used a propensity model to com-
pare the eff ect of the surgical treatment for 
hydrocephalus in similar patient groups. 
Th ree patients with a haemorrhage extending 
to the brainstem were excluded. In the 66 pro-
pensity-matched patients (33 in both groups), 
3-month mortality was signifi cantly lower 
in patients undergoing surgical treatment 
for hydrocephalus than in those who did not 
(33.3% vs. 66.7%, p = 0.007), while no diff er-
ences were observed in the variables used to 
construct the propensity score (Table 21).
Table 21. Propensity score-matched comparison between patients with surgical treatment for hyd-
rocephalus, either with EVD or cerebellar haematoma evacuation, and patients without surgical 
treatment. Th e variables denoted with an asterisk were not included in the calculation of the propen-
sity score.
Variable No surgical treatment for 
hydrocephalus (n=33)
Surgical treatment for 
hydrocephalus (n=33)
p
Age in years, mean (95% CI) 67.0 (61.0-73.0) 64.0 (59.6-68.4) 0.373
Haematoma volume in cm3, mean 
(95% CI)
20.1 (14.2-26.0) 27.7 (21.0-34.3) 0.082
Cerebellar ICH 18 (54.5%) 18 (54.5%) 1
GCS 3-8 on arrival, n (%) 15 (54.5.2%) 15 (54.5%) 1
Moderate or severe hydrocephalus, n 
(%)
26 (78.8%) 28 (84.8%) 0.523
GCS on arrival, median (IQR) * 11 (3-15) 11 (3-14) 0.657
IVH score, median (IQR) * 4 (1-7) 4 (2-6) 0.477











3-month mortality * 22 (66.7%) 11 (33.3%) 0.007
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5.4.4  Complications and shunt 
placement
Th e median duration of EVD treatment was 
7 days (IQR 3-11). Seven patients needed 
one EVD change, while one patient needed 
four catheter changes because of clogging. 
One patient received intraventricular rTPA 
to open a clogged EVD. Four patients (8.5%) 
had EVD-related meningitis, all treated with 
ceft azidime and vancomycin. Two patients 
received a lumbar drain for persistent hydro-
cephalus, and one of these was later shunted. 
In total, only six patients of 1075 received a 
shunt (0.6%). Th e median interval between 
ICH and shunt insertion was 12 days (IQR 
0-22). Two shunts needed revision; one was 
externalised and later revised because of clog-
ging, and one patient underwent shunt valve 
replacement because the initial valve resist-
ance was too high.  
5.5  ICH in the young 
(Publication IV)
In publication IV, we used a separate data of 
325 patients aged between 16 and 49 years that 
also included haemorrhages with macrovascu-
lar/structural causes. All consecutive patients 
admitted during a 10-year period, from Jan-
uary 2001 to March 2010, were included. We 
showed that surgical haematoma evacuation 
predicted a signifi cantly lower 3-month mor-
tality relative to patients treated conservatively 
(OR 0.06, 95% CI 0.02-0.21, p < 0.001).
5.5.1  Demographics and 
radiological fi ndings
Patients’ median age was 42 years (IQR 
34-47), with a slight (59.5%) male predom-
inance. Using the SMASH-U classifi cation3, 
the aetiology was hypertensive microangi-
opathy in 84 patients (26%), structural in 84 
(26%), other (including systemic diseases) in 
52 (16%), and unknown in 105 (32%). Of the 
structural haemorrhages, the bleed was caused 
by an AVM in 45 patients (13.4%), and by a 
cavernous angioma in 36 patients (10.7%). Th e 
median ICH volume was 11 ml (IQR 3-36 ml), 
and in 34.8% of the patients the haemorrhage 
extended to the ventricles. Th e majority of the 
patients were in good condition, the median 
GCS on arrival being 15 (IQR 10-15). 
5.5.2  Treatment
In total, 102 patients (31.4%) underwent 
craniotomy and haematoma evacuation. In 
addition, 6 patients (1.8%) needed a primary 
decompressive hemicraniectomy. Th irty-one 
patients (9.5%) received an EVD. Of the 
patients, 32% were treated in an acute stroke 
unit, 53% in a general or neurosurgical spe-
cialist ICU, and the remaining 15% in a neuro-
logical or neurosurgical ward. 
5.5.3  Predictors of three-month 
mortality
Th e 3-month mortality was 16.9%. Treatment 
was withdrawn in 46 patients (13.7%) and 
22 patients were eligible as potential organ 
donors. At discharge, 37.5% of patients were 
functionally independent (mRS 0-2). 
In multivariable regression, increasing 
NIHSS score, infratentorial location, hydro-
cephalus, multiple haemorrhages, and radio-
logical herniation were statistically signifi cant 
predictors of mortality at 3 months. By con-
trast, haematoma evacuation was signifi cantly 
associated with better probability of survival 
(OR 0.06, 95% CI 0.02-0.21, p < 0.001) (Table 
22). 
Because of diff erences between the oper-
ated and conservatively treated patient groups, 
we used a propensity score for matching the 
surgically and conservatively treated patients. 
In the matched patients, haematoma evacua-
tion was associated with 71% lower 3-month 
mortality (7.8% vs 27.5%, p < 0.001), even 
though the operated patients had larger hae-




Table 22. Results of the multivariate regression for 3-month mortality. 
Variable OR 95% CI p
Female sex 1.13 0.43-3.00 0.803












































Intraventricular blood 2.07 0.77-5.58 0.152
Hydrocephalus 4 1.61-9.9 0.003
Multiple haemorrhages 6.82 1.65-28.20 0.008
Radiological herniation 5.94 1.71-20.6 0.005
Haematoma evacuation 0.06 0.02-0.21 < 0.001
Table 23. Diff erences in propensity-matched surgically and conservatively treated patients.
Variable ICH evacuation (n=102) Conservative treatment (n=102) p
Female sex, n (%) 41 (40.2%) 39 (38.2%) 0.774
















































Intraventricular blood, n (%) 42 (41.2%) 37 (36.3%) 0.472
Hydrocephalus, n (%) 33 (32.4%) 26 (25.5%) 0.280
Multiple haemorrhages, n (%) 3 (2.9%) 5 (4.9%) 0.471
Radiological herniation, n 
(%)
28 (27.5%) 16 (15.7%) 0.041




6.1  Main findings
Diff erent prognostic scores for ICH abound 
in the literature, but the familiar and clinically 
widespread NIHSS score performed as well as 
the best dedicated prognostic scores in esti-
mating the risk of in-hospital death. For 3- and 
12-month mortality, the new ICH Functional 
Outcome Scale (ICH-FOS)193 performed best.
In addition, we showed that surgical treat-
ment of ICH was benefi cial, especially in cer-
tain subpopulations. When considering all 
patients with ICH, surgically treated patients 
had signifi cantly lower long-term mortality 
than conservatively managed patients, and the 
diff erence became more pronounced in a pro-
pensity score-matched comparison.
However, surgically treated patients with 
an intracerebellar haemorrhage did not show 
better short- or long-term survival than the 
ones treated conservatively. Surgery may have 
saved the patients’ lives, but the functional 
outcome was signifi cantly worse in the sur-
gically treated patients, similarly as shown in 
patients with a deep ICH already in the late 
1980s at Helsinki University Hospital11. 
ICH-related hydrocephalus was a clear 
predictor of high mortality and poor outcome, 
at least when left  untreated. When the ICH-re-
lated hydrocephalus was treated surgically by 
external ventricular drainage, shunt insertion, 
or evacuation of a cerebellar haemorrhage 
causing the hydrocephalus, the 3-month mor-
tality was signifi cantly lower. In a propensity 
score matched comparison, surgical treatment 
of hydrocephalus was associated with a 50% 
lower mortality than conservative treatment.
In the young, surgical evacuation of ICH 
was associated with a signifi cantly lower 
3-month mortality. Predictors of increased 
3-month mortality did not diff er from the 
previously known ones, including increas-
ing symptom severity, infratentorial location, 
hydrocephalus, radiological herniation, and 
presence of multiple haemorrhages.
6.2  Use of prognostic 
scores for ICH
In publication I, we found a total of 19 dif-
ferent prognostic scores and models for out-
come or mortality estimation aft er ICH. Our 
study was the fi rst to include all of the pub-
lished models, making them comparable in a 
large, single-centre cohort of consecutive ICH 
patients. Th e NIHSS score performed aston-
ishingly well in predicting in-hospital aft er 
ICH (AUC 0.825, 95% CI 0.790-0.860), while 
the ICH Functional Outcome Score (ICH-
FOS) was superior for 3-month and 12-month 
mortality (AUC 0.88 [95% CI 0.855-0.906] 
and 0.864 [0.838-0.891], respectively). In our 
analyses, most of the scores performed rea-
sonably well, with only the Tuhrim equation 
giving an AUC < 0.7 for 3-month mortality.
Th e National Institutes of Health Stroke 
Scale was originally created to assess neu-
rological impairment severity in ischaemic 
stroke patients, but it has since been vali-
dated for ICH as well207. It seems logical that 
the presentation neurological status should 
be predictive of outcome, at least short-term, 
and the fi nding is in line with previous results 
which suggest that GCS could suffi  ce for out-
come prediction in ICH patients208. Th e ICH-
FOS score includes both GCS and NIHSS 
scores as score components, reinforcing the 
importance of current neurological status and 
level of consciousness in outcome prediction. 
In addition to ICH-FOS, NIHSS was included 
in the modifi ed and new ICH scores187, the 
Essen ICH score188, and the Get With Th e 
Guidelines (GWTG) score168. Th ese do not, 
however, report the prognostic performance 
of the score components.
In ischaemic stroke, experienced clinicians’ 
ability to correctly predict 30-day mortal-
ity may be as low as 33.1%209, and compared 
with this fi gure, all of the scores performed 
extremely well. Th e three mathematical 
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models – Cincinnati model172, Masé model173, 
and Tuhrim equation174 – seem hard to imple-
ment in day-to-day clinical usage, although 
nowadays using a smartphone app or a com-
parable calculator soft ware might overcome 
this obstacle. Although there are no published 
data on the clinical usage of the diff erent 
scores, to our knowledge, only the ICH score 
is in widespread clinical use. 
Many of the scores seem to include the 
same variables as the original ICH score, with 
slight diff erences in point assignments. In 
addition to GCS as a measure of level of con-
sciousness, the original ICH score includes 
age, infratentorial location, ICH volume, 
and intraventricular extension.9 Th e ICH-
FOS score adds NIHSS, reinforcing the value 
of current clinical neurological status, and 
hyperglycemia as a sign of uncontrolled dia-
betes.193 Hydrocephalus has been found to be 
a signifi cant predictor of poor outcome, but it 
was not included in any of the scores.144 One 
explanation may be that ICH-related hydro-
cephalus is usually caused by intraventricular 
or infratentorial haemorrhage, both of which 
are incorporated in most prognostic models. 
Each new score aims at improving prog-
nostication in all or some subgroups of ICH 
patients - patients in hemodialysis210, patients 
in developing countries149, or a highly selected 
cohort for surgical intervention206. However, 
many of the scores have been developed based 
on very small or very selected patient cohorts, 
and while they are mainly based on the origi-
nal ICH score, diff erences in the point assign-
ments may be statistical consequences of dif-
ferences in the small derivation cohorts. In 
addition, some outcomes seem to be defi ned 
a posteriori. Most of the scores also use 
dichotomised or categorised variables, which 
may cause loss of information and statistical 
power.182
Selection of the score components in the 
19 models generally seems to have been based 
on choosing the “most signifi cant” variables 
in univariate analyses to be included in the 
regression model. In some circumstances, this 
could be helpful in fi nding new explanatory 
variables, but it may also result in omitting 
variables that are usually signifi cant but not 
in the derivation cohort, known as statistical 
“over-fi tting”.211 In publication I, we observed 
that the predictive performance of the ICH-
FOS score for 12-month mortality was in our 
analyses higher than in the original article 
(AUC 0.830 vs. 0.8642), and it seems that the 
ICH-FOS score was not statistically over-fi tted 
to the derivation population.193
Many authors have expressed concerns 
about “self-fulfi lling prophecies” in connec-
tion with the prognostic scores.194,212-215 Leav-
ing patients with a suspected poor prognosis 
without proper treatment probably accounts 
for an inevitable death, and if this has been 
done in the derivation cohorts, the model 
will inherently produce an estimate of a poor 
prognosis for similar patients.212 However, not 
only decisions to withhold treatment aff ect the 
prognostic model – all hidden confounders 
in the derivation cohorts are projected in the 
estimates produced by the prognostic model 
and may incorporate some unaccounted bias 
into the results.  At our institute, a new policy 
to guarantee all ICH patients with a suspected 
poor prognosis a possibility of admission to 
ICU minimises the risk of “too hasty” end-of-
life decisions and has, in addition, increased 
the number of potential organ donors sub-
stantially  216.
In our opinion, the prognostic scores may 
be helpful in scientifi c work, e.g. as inclusion 
criteria for prospective trials, but one should 
remain cautious in applying the results in indi-
vidual patients in clinical work and when com-
municating the risk of death to patients and 
relatives. Th e scores pose an ethical dilemma 
but do not give an answer – could there ever 
be such a threshold produced by a mathemat-
ical model alone, aft er which the treatment 
could or should be considered futile? 
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6.3  Surgical treatment 
of intracerebellar 
haemorrhage
In publication II, we studied a group of 114 
patients with a cerebellar ICH. Our aim was 
to compare functional outcome and long-term 
mortality in medically and surgically treated 
patients. 
Since the 1970s, a mutual understanding has 
existed among neurologists and neurosur-
geons that large (diameter over 3 cm) intra-
cerebellar haemorrhages need to be evacuated 
in patients with a declining level of conscious-
ness.137 Th is results in an innate selection bias 
towards patients with larger ICHs and more 
severe symptoms in the surgical group. 
Th is was refl ected in publication II. Signif-
icant diff erences were present in the baseline 
characteristics of surgically and conservatively 
treated patients. Th e operated patients were 
younger, had larger haemorrhages, and had 
lower level of consciousness on arrival.  Th ey 
suff ered more oft en from brainstem compres-
sion and hydrocephalus. Most patients were 
fi rst observed before proceeding to surgery, 
with a mean interval from admission to sur-
gery of 22.7 hours. Older patients with more 
comorbidities were more oft en treated con-
servatively.
No signifi cant diff erences emerged in 
short- or long-term mortality between sur-
gically and conservatively treated patients, 
but the surgically treated patients were left 
in a signifi cantly worse clinical condition, at 
least at hospital discharge. In the multivar-
iable logistic regression, age was associated 
with poor functional outcome at discharge or 
in-hospital death (mRS 4-6) in the age group 
of 65-80 years, but not in other age groups. 
Th is could be caused by referral bias; some 
elderly patients in poor condition may have 
been left  in primary hospitals. Hydrocepha-
lus217,218, brainstem compression138,219, fourth 
ventricle obstruction202, and quadrigeminal 
cistern obliteration201 were associated with 
poor outcome in the univariate analyses, but 
did not reach signifi cance in the multivariable 
regression model. Fourth ventricle obstruc-
tion or compression is considered the root 
cause of hydrocephalus in patients with intrac-
erebellar haemorrhage, while quadrigeminal 
cistern obstruction is thought to represent 
mass eff ect in the posterior fossa. In our series, 
GCS < 13 on admission led to a poor outcome 
without exception, consistent with previous 
studies.140,143,217,219
Very limited data are available on long-
term outcome aft er cerebellar ICH. In a Swed-
ish study, 62% of patients either died or had 
an unfavourable outcome in a long term (70-
month) follow-up.217 In publication II, the 
long-term mortality was 50% in medically 
and 47.4% in surgically treated patients aft er a 
mean follow-up of 34 months.  We used mRS 
1 to 3 at discharge as a sign of favourable func-
tional outcome, and the incidence was as low 
as 10.5% in surgically and 30.7% in conserva-
tively treated patients. Dolderer and co-work-
ers have previously reported similar fi gures, 
with only 14% of surgically treated patients 
having a favourable outcome in a long-term 
(49-month) follow-up.143 In addition, it has 
been shown that moderately disabled patients 
with a cerebellar ischaemic stroke recovered 
well, but a poor initial condition led to a poor 
rehabilitation outcome.220
Patients with a cerebellar ICH seem to be 
a group that oft en undergoes surgical treat-
ment, although the scientifi c proof of benefi ts 
is somewhat vague15 and treatment results are 
generally pessimistic.17 Th e concept of clinical 
equipoise means that there is uncertainty in 
the research community about the superiority 
of two treatment options, and this allows one 
to construct a trial testing these two treatments 
against each other.221 As surgery is usually 
considered the standard treatment in patients 
with a large intracerebellar haemorrhage and 
declining level of consciousness, clinical equi-
poise hardly exists. Th is makes constructing 
future prospective randomised trials ethically 
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diffi  cult. However, as we, among others, have 
shown, surgical treatment results leave much 
to be desired, and patients are left  in such a 
poor condition that it might be possible to 
randomise patients to conservative treatment 
instead of surgery should future investigations 
produce similar results. 
6.4  ICH-related 
hydrocephalus
In publication III, we compared the hydroce-
phalic and non-hydrocephalic ICH patients 
and observed that the hydrocephalic patients 
had a strikingly high in-hospital and 3-month 
mortality. Some of the eff ect was probably 
due to higher ICH volumes in hydrocephalic 
patients. Th ese results are in line with previ-
ous fi ndings, with the majority of the authors 
considering ICH-related hydrocephalus a state 
of very high mortality and a sign of poor out-
come.20,147
However, in patients who either under-
went cerebellar ICH evacuation or received an 
EVD or a shunt to treat the hydrocephalus, the 
mortality dropped signifi cantly, approaching 
the level of non-hydrocephalic patients (27.5% 
vs. 20.5%). In the propensity score analysis, 
surgical treatment of ICH-related hydroceph-
alus was associated with a 50% reduction in 
mortality. 
Previously, small non-lobar ICH, GCS less 
than 8, and severe IVH have been considered 
predictors of EVD treatment.150 In the same 
study, mortality was signifi cantly higher in 
patients who received an EVD than in patients 
who did not receive an EVD. In publication 
III, our surgically and non-surgically treated 
patients showed no diff erences in GCS on 
arrival, but the haemorrhage volumes were 
smaller in those patients whose hydroceph-
alus was treated surgically. In the surgically 
treated patients, the haemorrhages were more 
oft en located in the cerebellum and less oft en 
in the cortical or deep hemispheric areas. Th is 
refl ects both the strategic location of poste-
rior fossa in the pathogenesis of ICH-related 
hydrocephalus and the high tendency to oper-
ate on patients with cerebellar ICHs.15
Many of the ICHs in the hydrocephalic 
patients were situated in the cerebellum, caus-
ing not only hydrocephalus but brainstem 
compression as well. However, in publication 
II we showed in the same patients that evacua-
tion of an intracerebellar haemorrhage did not 
cause signifi cant diff erences in short- or long-
term mortality.
We constructed a propensity score to iso-
late the eff ect of hydrocephalus and compare 
mortality in matched pairs of hydrocephalic 
patients, half of whom received surgical treat-
ment for hydrocephalus, while the other half 
did not. We observed that in-hospital and 
3-month mortality were much lower in the 
group of surgically treated patients. Although 
we saw in pairwise comparisons that the con-
servatively treated patients more oft en had 
catastrophic bleeds and distorted, blood-fi lled 
ventricles, it is likely that the surgically treated 
patients would have had a much worse prog-
nosis had they been left  without surgical treat-
ment.
In publication III, the frequency of shunts 
was extremely low – only 0.6% of all patients 
with ICH or 9.8% of hydrocephalic ICH 
patients received a shunt. In previous stud-
ies, the frequency of shunts in ICH-related 
hydrocephalus has varied between 20% and 
29%.156,157 We could not assess factors asso-
ciated with shunt-dependent hydrocephalus 
due to the low number of patients receiving a 
shunt.
No good guidelines exist on when to treat 
ICH-related hydrocephalus or to insert an 
EVD, and hence, the treatment decisions are 
always made case-by-case. In an observational 
retrospective series, it is clear that the popu-
lations of treated and untreated patients have 
signifi cant diff erences. Some of the diff er-
ences are explained by referral bias; some of 
the patients may not have been referred to our 
hospital because of suspected grim prognosis 
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or they may have died before arrival. How-
ever, despite these shortcomings, we showed 
in publication III that surgical treatment of 
non-aneurysmal non-traumatic ICH patients 
with hydrocephalus was benefi cial and asso-
ciated with a substantially lower in-hospital 
and 3-month mortality. Th is raises the ques-
tion of whether the decision not to off er sur-
gical treatment to hydrocephalic ICH patients 
could be a self-fulfi lling prophecy.212
6.5  ICH in the young
In publication IV, we assessed the diff erent 
predictors of 3-month mortality in patients 
with ICH aged 16-49 years. Haematoma evac-
uation was associated with a signifi cantly 
lower 3-month mortality. In the multivaria-
ble regression model for 3-month mortality, 
haematoma evacuation was associated with 
an odds ratio of 0.06 (95% CI 0.02-0.21, p < 
0.001). Th is was in accordance with previous 
results; Lai and colleagues observed that hae-
matoma evacuation was associated with mor-
tality in a multivariable regression model with 
an odds ratio of 0.211 (95%CI 0.09-0.476, p 
< 0.001).164 When compared with the young-
est age group, the age groups 30-39 years and 
40-49 years were associated with a reduced 
risk of mortality in the multivariable regres-
sion, with odds ratios of 0.06 (95% CI 0.01-
0.35, p = 0.002) and 0.19 (95% CI 0.05-0.75, p 
= 0.017), respectively. 
We showed that predictors of mortality did 
not diff er from those previously reported for 
young164 or older patients: GCS < 8, infraten-
torial location, intraventricular blood, hydro-
cephalus, and haematoma volume > 30 ml.9,144 
Th e total 3-month mortality was 16.9%, sig-
nifi cantly lower than the mortality in all ICH 
patients in publications II and III. In previ-
ous studies, the reported mortality has varied 
between 20.4%222 and 26.1%223, although the 
latter study included aneurysmal ICHs as well.
In total, ICH was evacuated in 31.4% of 
patients (102 patients), and 1.8% (6 patients) 
underwent a decompressive craniectomy, one 
of which was a suboccipital craniectomy for 
an intracerebellar haemorrhage. In contrast to 
publications II and III, ICHs originating from 
macroscopic structural lesions (n=84, 25.8%) 
were included and 41 (48.8%) of these patients 
underwent haematoma evacuation. 
6.6  Surgical treatment of 
ICH in the whole study 
population
When looking at the whole population with 
a non-traumatic, non-aneurysmal ICH aft er 
exclusion of macroscopic vascular/structural 
haemorrhages, we observed that the 3-month 
mortality was 36.6% and median survival 
time was 4.86 years (95% CI 4.07-5.66), com-
pared with corresponding national fi gures of 
35% and 4.5 years.29 Relative to conservatively 
treated patients, the long-term mortality was 
substantially lower in the patients who had 
undergone ICH evacuation. In Cox propor-
tional hazards univariate analyses, higher age, 
lower GCS and increasing haematoma volume 
were signifi cantly associated with a higher 
risk of death in long-term follow-up. Th e 
same observation was made in a multivariable 
analysis. Other predictors of poor outcome, 
such as ICH location, hydrocephalus severity, 
and IVH, did not meet the proportionality 
assumption and could not be included in the 
model. 
6.7  Strengths and 
limitations of the 
study
To the best of our knowledge, our study is 
one of the largest consecutive single-centre 
series published. It includes all patients with a 
spontaneous, non-traumatic, non-aneurysmal 
ICH treated at our tertiary university teaching 
hospital during a fi ve-year period. However, 
due to the observational and retrospective 
nature of the study, some selection and referral 
bias surely exist. Patients may not have been 
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referred to our unit, or they may have died 
before arrival to hospital. Th is may apply espe-
cially to patients in the oldest age groups, as 
patients with minor, or the most catastrophic 
bleeds may have been left  in the admitting 
hospitals. However, as neither neurosurgical 
treatment nor neurosurgical intensive care 
was available in other institutions in our area, 
all patients in need of tertiary-level care and 
expertise were included in our series. In publi-
cation IV, we might not have found all patients 
with a bleed originating from a tumour, pos-
sibly because they were not given an ICH-re-
lated ICD-10 code. We did not have a protocol 
for imaging studies, and therefore, the major-
ity of the patients (86.7%) did not undergo an 
MRI. In addition, we only used CTA to exclude 
vascular malformations instead of DSA, which 
is the gold standard and still superior to CTA, 
despite the recent advances in CT-based imag-
ing.224 Autopsies or surgical biopsies were 
obtained in very few patients. Hence, the aeti-
ological classifi cation may be inaccurate and 
is mainly based on the concept of ‘most likely 
aetiologies’.3 Traumatic or aneurysmal haem-
orrhages were not included in the study, and 
we decided to exclude haemorrhages related to 
arteriovenous malformations, cavernous angi-
omas, and dural fi stulae in publications II and 
III as well.
As no good guidelines exist, criteria for 
surgical treatment were not protocol- or 
guideline-based. Instead, the need for a surgi-
cal intervention was carefully considered for 
each patient, weighing the patient’s age, level 
of consciousness, comorbidities, symptoms, 
and haematoma location. Especially consid-
ering surgical treatment of hydrocephalus, 
the surgically treated patients present only a 
minor subset of all hydrocephalic patients. 
However, they seem to have benefi ted from 
surgical treatment. 
One of the main limitations of the study is 
the heterogeneity in baseline characteristics 
of both conservatively and surgically treated 
patients. As the need for surgery was individu-
ally considered for every patient, the surgically 
treated patients tended to be younger, more 
symptomatic, and have larger ICHs. Many of 
these diff erences explain why the treatment 
decisions were made. Th is can be observed 
especially in the patients with a cerebellar 
ICH, where the surgically treated patients 
would probably have died if left  untreated. 
Where suitable, we tried to overcome this 
obstacle by using a propensity score to match 
surgically treated patients with conservatively 
treated controls sharing the same baseline 
characteristics. Although the resulting groups 
were balanced, the cases and controls may still 
have had signifi cant diff erences in pairwise 
comparisons.
Unfortunately, we lack long-term func-
tional outcome data for these patients. In addi-
tion, our propensity score analyses would have 
benefi ted from a larger sample, as the num-
bers of surgically treated patients were rather 
low and the baseline diff erences between the 
surgically and conservatively treated patients 
posed diffi  culties in fi nding properly matched 
patients.  
6.8  Future prospects in 
ICH treatment and 
research
While the treatment options for ischae-
mic stroke have seen enormous progress 
during the last years, treatment of ICH has 
not evolved much in the last decades. Multi-
ple large-scale randomised controlled studies 
(RCTs), the best available means to compare 
two treatments with minimal bias, have been 
conducted on treatment of ICH patients. Very 
few treatment options, including surgical 
treatment and haematoma evacuation, have 
shown to have a signifi cant eff ect on mortal-
ity in RCTs. Current guidelines support rapid 
neuroimaging, medical treatment of clinical 
seizures, blood pressure lowering, treatment 
in specialist acute stroke unit, use of inter-
mittent pneumatic stockings to prevent deep 
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venous thrombosis, and multidisciplinary 
rehabilitation.
Since very limited treatment strategies exist 
aft er the haemorrhage has occurred, the key to 
minimising ICH-related global disease burden 
is prevention. As the incidence of ICH has 
increased especially in low- and middle-in-
come countries, it is important to encourage 
the use of antihypertensive medication and 
to facilitate access to primary and preventive 
health care in developing areas. Large regional 
disparities exist in access to neurologists even 
in wealthy countries, let alone less developed 
communities.
Instead of creating new prognostic scores 
for ICH, the stroke community should be 
aware of the risk of self-fulfi lling prophe-
cies and hasty decisions to withdraw care in 
patients with a suspected grim prognosis, e.g. 
patients with ICH-related hydrocephalus. Th e 
prognostic scores can be used to complement 
clinical decision-making, but they should be 
used with caution.
One possibility to search for the opti-
mal strategy for treatment of intracerebellar 
haemorrhages and to assess the futility of care 
would be to measure the long-term survi-
vors’ health-related quality of life. Also useful 
would be to compare the outcome of surgically 
and conservatively treated patients in a large, 
multicentre propensity-matched case-control 
study.
Strategies to minimise ICH-related 
oedema, limit haematoma expansion, and 
decrease the occurrences warrant more 
research. As the aetiological classifi cation is 
probabilistic by nature and tissue samples are 
seldom gathered, the defi nitive haemorrhage 
aetiologies are still largely unknown. Genome-
wide analysis of single-nucleotide polymor-
phisms associated with CAA or hyperten-
sive microangiopathy could shed light on the 
pathogenesis and facilitate the prevention 
of ICH. In addition, fi nding new drug mole-
cules that could improve the removal of iron 
breakup products, thus helping to decrease 
cerebral oedema is of high importance, as are 
studying immunological reactions in the hae-





1. Th e best tools for mortality prognostication aft er ICH were NIHSS score for estima-
tion of in-hospital mortality, and ICH-FOS score for 3- and 12-month mortality. Many 
of the scores shared similar point assignments, derived from the original ICH score. 
Hydrocephalus has been found to be a signifi cant predictor of poor outcome, but it 
was not included in any of the scores. Prognostic scores may be helpful in scientifi c 
work, e.g. as inclusion criteria for prospective trials, but clinicians should be aware of 
the risks associated with possible self-fulfi lling prophecies.
2. Surgical treatment of intracerebellar haemorrhage was not associated with better 
short- or long-term survival than conservative management, although it is probable 
that surgical treatment did succeed in preventing mortality in patients who otherwise 
would have died. Functional outcome of the surviving patients remained worse aft er 
surgical treatment than aft er conservative management. Current treatment guidelines 
support surgical treatment in patients with large intracerebellar haemorrhages and 
declining level of consciousness. However, the outcomes aft er surgery may not be as 
good as we neurosurgeons tend to think, and that the long-term functional outcome 
needs further studies because of the rather pessimistic short-term functional outcome 
and high long-term mortality.
3. Surgical treatment of ICH-related hydrocephalus was benefi cial and in comparison to 
conservative management, it was associated with a substantially lower in-hospital and 
3-month mortality. Th e hydrocephalic patients had a strikingly high in-hospital and 
3-month mortality. As no good guidelines exist on when to treat ICH-related hydro-
cephalus or to insert an EVD, the treatment decisions are always made case-by-case. 
In the propensity score analysis, surgical treatment of ICH-related hydrocephalus 
was associated with a 50% reduction in mortality. Th is raises the question of whether 
the decision not to off er surgical treatment to hydrocephalic ICH patients could be a 
self-fulfi lling prophecy. 
4. In young adults, ICH evacuation was clearly associated with a decrease in mortality 
when compared with conservatively treated patients. In addition, the total 3-month 
mortality was 16.9%, signifi cantly lower than the mortality in all ICH patients. Increas-
ing symptom severity, infratentorial location, hydrocephalus, radiological herniation, 
and presence of multiple haemorrhages were associated with a higher 3-month mor-
tality. Although not generalizable to the whole population, our results support ICH 
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